Theralink (THER) 10-Q 11 Jun 21 2020 Q3 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	9 Months Ended
	Jun. 30, 2020	Jun. 09, 2021
Cover [Abstract]
Entity Registrant Name	THERALINK TECHNOLOGIES, INC.
Entity Central Index Key	0001362703
Document Type	10-Q
Document Period End Date	Jun. 30, 2020
Amendment Flag	false
Current Fiscal Year End Date	--09-30
Entity Current Reporting Status	No
Entity Interactive Data Current	No
Entity Filer Category	Non-accelerated Filer
Entity Small Business Flag	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	false
Entity Shell Company	false
Entity Common Stock, Shares Outstanding		5,555,473,158
Document Fiscal Period Focus	Q3
Document Fiscal Year Focus	2020

Condensed Consolidated Balance

Condensed Consolidated Balance Sheets - USD ($)	Jun. 30, 2020	Sep. 30, 2019
CURRENT ASSETS:
Cash	$ 934,196	$ 560,407
Accounts receivable	24,975	4,000
Prepaid expenses and other current assets	131,138	9,054
Total Current Assets	1,090,309	573,461
OTHER ASSETS:
Property and equipment, net	747,055	298,910
Finance right-of-use asset, net	169,905	204,059
Operating right-of-use asset, net	214,948
Marketable securities	6,800	18,000
Security deposit	19,464	7,790
Total Assets	2,248,481	1,102,220
CURRENT LIABILITIES:
Accounts payable	352,110	668,246
Accrued liabilities	128,907	118,241
Accrued compensation	6,547	297,056
Convertible debt, net		217,591
Notes payable - current	1,000	40,000
Financing right-of-use liability - current	40,969	35,096
Operating right-of-use liability - current	34,450
Due to related parties		180,000
Contingent Liabilities	62,240
Liabilities of discontinued operations	245,113
Total Current Liabilities	871,336	1,556,230
LONG-TERM LIABILITIES:
Financing right-of-use liability	147,162	178,350
Operating right-of-use liability	186,473
Total Liabilities	1,204,971	1,734,580
Commitments and contingencies (Note 10)
STOCKHOLDERS' EQUITY (DEFICIT):
Preferred stock: $0.0001 par value; 26,667 authorized; 13,672 and 992 issued and outstanding at June 30, 2020 and September 30, 2019, respectively
Common stock: $0.0001 par value, 12,000,000,000 shares authorized; 1,398,070 and 0 issued and outstanding at June 30, 2020 and September 30, 2019, respectively	140
Additional paid-in capital	40,891,726	37,378,841
Accumulated deficit	(39,848,356)	(38,011,201)
Total Stockholders' Equity (Deficit)	1,043,510	(632,360)
Total Liabilities and Stockholders' Equity (Deficit)	$ 2,248,481	$ 1,102,220

Condensed Consolidated Balanc_2

Condensed Consolidated Balance Sheets (Parenthetical) - $ / shares	Jun. 30, 2020	Sep. 30, 2019
Statement of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	26,667	26,667
Preferred stock, shares issued	13,672	992
Preferred stock, shares outstanding	13,672	992
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	12,000,000,000	12,000,000,000
Common stock, shares issued	1,398,070	0
Common stock, shares outstanding	1,398,070	0

Condensed Consolidated Statemen

Condensed Consolidated Statements of Operations (Unaudited) - USD ($)	3 Months Ended		9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019
Income Statement [Abstract]
REVENUES, NET	$ 24,886		$ 75,896
COST OF REVENUE	7,422		23,421
GROSS PROFIT	17,464		52,475
OPERATING EXPENSES:
Professional fees	322,921	139,780	470,638	396,089
Consulting fee - related party	8,650	51,242	64,125	206,767
Compensation expense	372,610	69,380	822,329	228,815
Licensing fees	12,750	12,886	38,920	39,046
General and administrative expenses	258,277	102,092	636,838	244,070
Total Operating Expenses	975,208	375,380	2,032,850	1,114,787
LOSS FROM OPERATIONS	(957,744)	(375,380)	(1,980,375)	(1,114,787)
OTHER INCOME (EXPENSE):
Interest expense	(7,844)	(11,951)	(23,715)	(53,755)
Gain on debt extinguishment	108,060		108,060
Unrealized loss on marketable securities	(4,900)	(9,100)	(11,200)	(14,400)
Loss on legal judgement		(30,100)		(30,100)
Foreign currency transaction gain	60,075		60,075
Other income	10,000		10,000
Total Other Income (Expense), net	165,391	(51,151)	143,220	(98,255)
NET LOSS	$ (792,353)	$ (426,531)	$ (1,837,155)	$ (1,213,042)
NET LOSS PER COMMON SHARE:
Basic	$ (2.04)	$ (2.53)	$ (19.19)	$ (7.20)
Diluted	$ (2.04)	$ (2.53)	$ (19.19)	$ (7.20)
WEIGHTED AVERAGE COMMON SHARES OUTSTANDING:
Basic	388,333	168,479	95,753	168,479
Diluted	388,333	168,479	95,753	168,479

Condensed Consolidated Statem_2

Condensed Consolidated Statement of Changes in Stockholders' Equity (Deficit) (Unaudited) - USD ($)	Preferred Stock [Member]	Common Stock [Member]	Additional Paid-in Capital [Member]	Accumulated Deficit [Member]	Total
Balance at Sep. 30, 2018			$ 35,600,822	$ (36,413,367)	$ (812,545)
Balance, shares at Sep. 30, 2018	961
Preferred stock issued for cash			259,470		259,470
Preferred stock issued for cash, shares	1
Net loss				(468,063)	(468,063)
Balance at Dec. 31, 2018			35,860,292	(36,881,430)	(1,021,138)
Balance, shares at Dec. 31, 2018	962
Balance at Sep. 30, 2018			35,600,822	(36,413,367)	(812,545)
Balance, shares at Sep. 30, 2018	961
Net loss					(1,213,042)
Balance at Jun. 30, 2019			36,200,393	(37,626,409)	(1,426,016)
Balance, shares at Jun. 30, 2019	989
Balance at Dec. 31, 2018			35,860,292	(36,881,430)	(1,021,138)
Balance, shares at Dec. 31, 2018	962
Preferred stock issued for cash			60,000		60,000
Preferred stock issued for cash, shares
Net loss				(318,448)	(318,448)
Balance at Mar. 31, 2019			35,920,292	(37,199,878)	(1,279,586)
Balance, shares at Mar. 31, 2019	962
Preferred stock issued for cash			280,000		280,000
Preferred stock issued for cash, shares	1
Common stock issued for services			101		101
Common stock issued for services, shares	26
Net loss				(426,531)	(426,531)
Balance at Jun. 30, 2019			36,200,393	(37,626,409)	(1,426,016)
Balance, shares at Jun. 30, 2019	989
Balance at Sep. 30, 2019			37,378,841	(38,011,201)	(632,360)
Balance, shares at Sep. 30, 2019	992
Preferred stock issued for cash			2,200,000		2,200,000
Preferred stock issued for cash, shares	6
Preferred stock issued upon debt conversions			277,215		277,215
Preferred stock issued upon settlement of accrued compensation			239,154		239,154
Preferred stock issued upon settlement of accrued compensation, shares	1
Net loss				(541,372)	(541,372)
Balance at Dec. 31, 2019			40,095,210	(38,552,573)	1,542,637
Balance, shares at Dec. 31, 2019	999
Balance at Sep. 30, 2019			37,378,841	(38,011,201)	(632,360)
Balance, shares at Sep. 30, 2019	992
Net loss					(1,837,155)
Balance at Jun. 30, 2020		$ 140	40,891,726	(39,848,356)	1,043,510
Balance, shares at Jun. 30, 2020	13,671	1,398,070
Balance at Dec. 31, 2019			40,095,210	(38,552,573)	1,542,637
Balance, shares at Dec. 31, 2019	999
Preferred stock issued for cash			390,000		390,000
Preferred stock issued for cash, shares	1
Preferred stock issued upon settlement of accrued compensation			160,000		160,000
Net loss				(503,430)	(503,430)
Balance at Mar. 31, 2020			40,645,210	(39,056,003)	1,589,207
Balance, shares at Mar. 31, 2020	1,000
Recapitalization resulting from the Asset Sale Transaction (see Note 3)		$ 140	246,516		246,656
Recapitalization resulting from the Asset Sale Transaction (see Note 3), shares	12,671	1,398,070
Net loss				(792,353)	(792,353)
Balance at Jun. 30, 2020		$ 140	$ 40,891,726	$ (39,848,356)	$ 1,043,510
Balance, shares at Jun. 30, 2020	13,671	1,398,070

Condensed Consolidated Statem_3

Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)	9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
CASH FLOWS USED IN OPERATING ACTIVITIES
Net loss	$ (1,837,155)	$ (1,213,042)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation	57,060	33,365
Lease expense	5,975
Stock issued for services		101
Amortization of debt discount		25,000
Gain on debt extinguishment	(108,060)
Foreign Currency transaction gain	(60,075)
Unrealized loss on marketable securities	11,200	14,400
Change in operating assets and liabilities:
Accounts receivable	(20,975)
Prepaid expenses and other current assets	(116,219)	(14,337)
Accounts payable	(212,840)	177,476
Accrued liabilities and other liabilities	(70,734)	110,369
Due to related parties		100,647
NET CASH USED IN OPERATING ACTIVITIES	(2,351,823)	(766,021)
CASH FLOWS FROM INVESTING ACTIVITIES
Cash acquired from the Asset Sale Transaction (see Note 3)	675,928
Purchase of property and equipment	(495,557)	(18,746)
NET CASH PROVIDED BY (USED IN) INVESTING ACTIVITIES	180,371	(18,746)
CASH FLOWS FROM FINANCING ACTIVITIES
Proceeds from sale of preferred stock	2,590,000	599,470
Proceeds from convertible debt, net of debt discount		100,000
Repayment of related party advances, net	(20,000)	114,610
Repayment of convertible debt	(24,759)	(10,000)
NET CASH PROVIDED BY FINANCING ACTIVITIES	2,545,241	804,080
NET CHANGE IN CASH	373,789	19,313
CASH, beginning of the period	560,407	20,896
CASH, end of the period	934,196	40,209
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Interest
Income taxes
Non-cash investing and financing activities:
Issuance of preferred stock for convertible debt and interest	277,215
Issuance of preferred stock for settlement of accounts payable and accrued liabilities	399,154
Net assets acquired from Asset Sale Transaction (see Note 3)
Cash	675,928
Prepaid expense and other current assets	17,539
Accounts payable and other liabilities	(40,149)
Liabilities of discontinued operations	(406,662)
Net assets acquired	$ 246,656

Organization and Nature of Oper

Organization and Nature of Operations	9 Months Ended
	Jun. 30, 2020
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization and Nature of Operations	NOTE 1 - ORGANIZATION AND NATURE OF OPERATIONS Theralink Technologies, Inc., formerly OncBioMune Pharmaceuticals, Inc. (the “Company”), was a clinical-stage biopharmaceutical company engaged in the development of novel cancer immunotherapy products, with a proprietary vaccine technology. On June 5, 2020, the Company acquired the assets (the “Asset Sale Transaction”) of Avant Diagnostics, Inc., a Nevada corporation established in 2009 (“Avant”) pursuant to the Asset Purchase Agreement dated May 12, 2020 between the Company and Avant (the “Asset Purchase Agreement”). Avant is a commercial-stage precision medicine and molecular data-generating company that focuses on the development and commercialization of a series of patented, proprietary data-generating assays that may provide important actionable information for physicians and patients, as well as biopharmaceutical companies, in the areas of oncology. Pursuant to the Asset Purchase Agreement, the Company acquired substantially all of the assets of Avant and assumed certain of its liabilities. Upon the terms and subject to the conditions of the Asset Purchase Agreement, Avant sold to the Company, all of Avant’s title and interest in, to and under all of the assets, properties and rights of every kind and nature, whether real, personal or mixed, tangible or intangible (including goodwill), wherever located and whether existing or hereafter acquired, except for the specific excluded assets, which relate to, or are used or held for use in connection with, Avant’s business. The Company also hired Avant’s employees upon consummation of the Asset Sale Transaction. As consideration for the Asset Sale Transaction, the Company issued to Avant 1,000 shares of a newly created Series D-1 Preferred Stock which held 54.55% of all voting rights on an as-converted basis with the common stock. Upon the effectiveness of an increase of the Company’s authorized shares of common stock from 6,666,667 shares to 12,000,000,000 shares, all such shares of Series D-1 Preferred Stock issued to Avant automatically converted into 5,081,549,184 shares of the Company’s common stock. Avant possessed majority voting control of the Company immediately following the Asset Sale Transaction and controlled the Company’s Board of Directors after the termination of the ten-day waiting period required by Rule 14f-1 under the Exchange Act. Accordingly, the Asset Sale Transaction was accounted for, in substance, as an asset acquisition of the Company’s net asset by Avant and a recapitalization of Avant . On June 5, 2020, pursuant to the Asset Purchase Agreement, the Company; (i) entered into an employment agreement with Dr. Michael Ruxin to serve as the Company’s Chief Executive Officer, President and a director (see Note 10); (ii) entered into an employment agreement with Jeffery Busch to serve as the Company’s Chairman of the Board of Directors (see Note 10) and; (iii) appointed Yvonne Fors to its Board of Directors. On June 11, 2020, the Company filed a Certificate of Withdrawal of Designation with the Nevada Secretary of State terminating the designation, amount thereof, voting powers, preferences and relative participating, optional and other special rights of the shares of the preferred stock of the Company designated as Series B Preferred Stock (see Note 9). On August 14, 2020, the Board appointed Mr. Andrew Kucharchuk as Acting Chief Financial Officer of the Company, effective immediately (see Note 11). On August 14, 2020, the Board approved a change in the Company’s fiscal year end from December 31 to September 30, effective immediately for the current fiscal year, and for all subsequent years until such time as the Board resolves to amend such fiscal year end. The fiscal year has been changed to conform to the September 30 fiscal year end of Avant which is the historical registrant as a result of the Asset Sale Transaction consummated on June 5, 2020 and therefore, no transition report is required (see Note 11). On September 15, 2020, the Company filed a certificate of designation, preferences and rights of Series E Preferred Stock (the “Series E Certificate of Designation”) with the Nevada Secretary of the State of to designate 2,000 shares of its previously authorized preferred stock as Series E Preferred Stock, par value $0.0001 per share and a stated value of $2,000 per share. The Series E Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law (see Note 11). On September 22, 2020, the Company filed with the Nevada Secretary of State an amendment to its Certificate of Incorporation to change its name from “OncBioMune Pharmaceutical, Inc.” to “Theralink Technologies, Inc.” and increase its authorized shares of common stock from 6,666,667 shares of common stock at $0.0001 per share par value to 12,000,000,000 shares of common stock at $0.0001 per share par value, effective September 24, 2020 (see Note 9 and Note 11). The 1,000 shares of Series D-1 Preferred stock and 4,121.6 shares of Series D-2 Preferred stock were automatically converted into 5,081,549,184 and 41,216,000 shares of common stock, respectively, upon increase of the authorized shares, pursuant to the Certificate of Designations (see Note 11). The change in authorize shares has been retroactively reflected in the accompanying consolidated balance sheets. On September 24, 2020, Andrew Kucharchuk resigned from his position as Acting Chief Financial Officer, effective immediately. Mr. Kucharchuk continues to serve as a director on the Company’s Board of Directors. On the same day, the Company appointed Thomas E. Chilcott, III, to serve as the Chief Financial Officer (see Note 11).

Summary of Significant Accounti

Summary of Significant Accounting Policies	9 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Summary of Significant Accounting Policies	NOTE 2 – SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES Basis of Presentation and Principles of Consolidation The accompanying interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information, which present the consolidated financial statements of the Company and its wholly-owned subsidiary as of June 30, 2020. All intercompany transactions and balances have been eliminated. On April 4, 2021, the Company filed with the SEC the audited restated financial statements of Avant for the fiscal year ended September 30, 2019 and related notes on Amendment No. 2 to its Current Report on Form 8-K/A. Accordingly, the interim audited condensed consolidated financial statements do not include all the information and notes necessary for a comprehensive presentation of financial position and results of operations and should be read in conjunction with the audited financial statements of Avant for the year ended September 30, 2019. It is management’s opinion that all material adjustments (consisting of normal recurring adjustments and non-recurring adjustments) have been made, which are necessary for a fair financial statement presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year ending September 30, 2020. These interim condensed consolidated financial statements for the period ending June 30, 2020 consist of the interim condensed consolidated balance sheets of the Company as of June 30, 2020 and the related interim condensed consolidated statements of operations, changes in stockholders’ equity (deficit) and cash flows for the three and nine month periods ended June 30, 2020 and 2019, and the related notes, and reflect the acquisition of the Company’s net assets pursuant to the Asset Sale Transaction with Avant Diagnostics, Inc. and concurrent recapitalization, which was consummated on June 5, 2020, as more fully disclosed in Note 3. Going Concern These consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company had net loss and net cash used in operations of $1,837,155 and $2,351,823, respectively, for the nine months ended June 30, 2020. Additionally, the Company had an accumulated deficit, stockholders’ equity and working capital of $39,848,356, $1,043,510 and $218,973 at June 30, 2020. Management believes that these matters raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the issuance date of this report. The Company cannot provide assurance that it will ultimately achieve profitable operations or become cash flow positive or raise additional debt or equity capital. Additionally, the current capital resources are not adequate to continue operating and maintaining the business strategy for a period of twelve months from the issuance date of this report. The Company will seek to raise capital through additional debt and equity financings to fund its operations in the future. Although the Company has historically raised capital from sales of equity and from the issuance of promissory notes, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail or cease operations. These consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The global pandemic COVID-19, otherwise referred to as the Coronavirus, could impair our ability to raise additional funding or make such funding more costly. The ongoing global pandemic has caused cessation of normal business operations and caused capital markets to decline sharply. This could make it more difficult for the Companies to access capital. It is currently difficult to estimate with any certainty how long the pandemic and resulting curtailment of business will continue, and its effect on capital markets and the Company’s ability to raise funds is, accordingly, difficult to quantify. In addition, to the extent that any of the Company’s personnel or consultants are affected by the virus, this could cause delays or disruption in our planned research and development activities. Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions, and estimates that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Management bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates during the nine months ended June 30, 2020 and year ended September 30, 2019 include, but are not necessarily limited to, the valuation of assets and liabilities of discontinued operations, estimates of contingent liabilities, valuation of marketable securities, useful life of property and equipment, valuation of right-of-use (“ROU”) assets and operating lease liabilities, assumptions used in assessing impairment of long-term assets, allowances for sales returns, estimates of current and deferred income taxes and deferred tax valuation allowances and the fair value of non-cash equity transactions. Additionally, the full impact of COVID-19 is unknown and cannot be reasonably estimated. However, the Company has made appropriate accounting estimates based on the facts and circumstances available as of the reporting date. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operation will be affected. Fair Value of Financial Instruments and Fair Value Measurements FASB ASC 820 - Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on June 30, 2020. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2—Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3—Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. In August 2018, the FASB issued ASU 2018-13 —Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement Cash For purposes of the consolidated statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less at the purchase date and money market accounts to be cash equivalents. At June 30, 2020 and September 30, 2019, the Company did not have any cash equivalents. The Company maintains its cash in banks and financial institutions that at times may exceed federally insured limits. There were cash balances in excess of FDIC insured levels as of June 30, 2020 and September 30, 2019. The Company has not experienced any losses in such accounts through June 30, 2020. Property and Equipment Fixed assets are stated at cost and depreciated using the straight-line method over their estimated useful lives, which range from three to five years. Leasehold improvements are depreciated over the shorter of the useful life or lease term including scheduled renewal terms. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable. Impairment of Long-Lived Assets In accordance with ASC Topic 360, the Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value. Stock-Based Compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC 505-50 - Equity-Based Payments to Non-Employees, all share-based payments to non-employees, including grants of stock options, were recognized in the consolidated financial statements as compensation expense over the service period of the consulting arrangement or until performance conditions are expected to be met. Using a Black Scholes valuation model, the Company periodically reassessed the fair value of non-employee options until service conditions are met, which generally aligns with the vesting period of the options, and the Company adjusts the expense recognized in the consolidated financial statements accordingly. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions by expanding the scope of the stock-based compensation guidance in ASC 718 to include share-based payment transactions for acquiring goods and services from non-employees. ASU No. 2018-07 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted, but entities may not adopt prior to adopting the new revenue recognition guidance in ASC 606. The Company early adopted ASU No. 2018-07 during the period September 30, 2018, and the adoption did not have any impact on its consolidated financial statements. Revenue Recognition In May 2014, FASB issued an Accounting Standards Update, ASU 2014-09, establishing ASC 606 - Revenue from Contracts with Customers. ASU 2014-09, as amended by subsequent ASUs on the topic, establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard, which is effective for interim and annual reporting periods in fiscal years that begin after December 15, 2017, requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. The Company adopted this standard during the fiscal year ended September 30, 2018 using the modified retrospective approach, which requires applying the new standard to all existing contracts not yet completed as of the effective date and recording a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Based on an evaluation of the impact ASU 2014-09 will have on the Company’s sources of revenue, the Company has concluded that ASU 2014-09 did not have any impact on the process for, timing of, and presentation and disclosure of revenue recognition from customers and there was no cumulative effect adjustment. The Company had $24,886 and $75,896 of revenues from operations during the three and nine months ended June 30, 2020. Cost of Revenue The cost of revenue consists of the cost of labor, supplies and materials. Accounts Receivable and Allowance for Doubtful Accounts Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis and do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. The allowance for doubtful accounts was $0 at June 30, 2020 and September 30, 2019. Basic and Diluted Loss Per Share Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. Potentially dilutive common shares consist of common stock issuable for stock options and warrants (using the treasury stock method), convertible notes and common stock issuable. These common stock equivalents may be dilutive in the future. The following potentially dilutive equity securities outstanding as of June 30, 2020 and 2019 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive: June 30, 2020 2019 Stock warrants 856,674,588 — Series C-1 preferred stock 445,301,289 — Series C-2 preferred stock 733,542,619 — Series D-1 preferred stock 4,441,433,275 4,392,557,509 Series D-2 preferred stock 41,216,000 — 6,518,167,771 4,392,557,509 Income Taxes The Company accounts for income tax using the liability method prescribed by ASC 740 - Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 “Income Taxes Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests. Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases On January 1, 2019, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize right-of-use (“ROU”) assets and lease liabilities for short-term leases that have a term of 12 months or less. Operating lease ROU assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the condensed consolidated statements of operations. Recent Accounting Pronouncements The Company reviewed the recent accounting pronouncements and determined that none of the recent accounting pronouncements were applicable. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company’s consolidated financial statements.

Asset Sale and Recapitalization

Asset Sale and Recapitalization Transaction	9 Months Ended
	Jun. 30, 2020
Business Combination and Asset Acquisition [Abstract]
Asset Sale and Recapitalization Transaction	NOTE 3 – ASSET SALE AND RECAPITALIZATION TRANSACTION Avant provides personalized medical data through its Theralink® assays, initially for breast cancer, to assist the treating physician in a data-driven process for treatment decision support and to help enable predictive biomarker-based patient therapy selection. Avant is a developer of phosphoproteomic technologies for measuring the activation state of therapeutic targets and signaling pathways, a key metric for biopharmaceuticals, with applications across multiple cancer types, including breast, non-small cell lung, colorectal, gynecologic and pancreatic, among others. On June 5, 2020, the Company closed the Asset Purchase Agreement entered into with Avant on May 12, 2020. Pursuant to the Asset Purchase Agreement, the Company acquired substantially all of the assets and business of Avant and assumed certain of its liabilities in the Asset Sale Transaction. Upon the terms and subject to the conditions of the Asset Purchase Agreement, Avant sold to the Company, all of Avant’s title and interest in, to and under all of the assets, properties and rights of every kind and nature, whether real, personal or mixed, tangible or intangible (including goodwill), wherever located and whether existing or hereafter acquired, except for the specific excluded assets, which relate to, or are used or held for use in connection with, Avant’s business. The Company also hired Avant’s employees upon consummation of the Asset Sale Transaction. As consideration for the Asset Sale Transaction, Avant was issued 1,000 shares of a newly created Series D-1 Preferred Stock which held 54.55% of all voting rights on an as-converted basis with the common stock. Upon the increase of the Company’s authorized shares of common stock from 6,666,667 shares to 12,000,000,000 shares effective September 24, 2020, all such shares of Series D-1 Preferred Stock issued to Avant automatically converted into 5,081,549,184 shares of the Company’s common stock. Avant possessed majority voting control of the Company immediately following the Asset Sale Transaction and controlled the Company’s Board of Directors after the termination of the ten-day waiting period required by Rule 14f-1 under the Exchange Act. Accordingly, the Asset Sale Transaction was accounted for, in substance, as an asset acquisition of the Company’s net assets by Avant and a recapitalization of Avant as discussed in detail below under “Accounting for the Asset Sale Transaction”. On June 5, 2020, pursuant to the Asset Purchase Agreement, the Company; (i) entered into an employment agreement with Dr. Michael Ruxin to serve as the Company’s Chief Executive Officer, President and a director (see Note 10); (ii) entered into an employment agreement with Jeffery Busch to serve as the Company’s Chairman of the Board of Directors (see Note 10) and; (iii) appointed Yvonne Fors to its Board of Directors. Accounting for the Asset Sale Transaction The Asset Sale Transaction was accounted for, in substance, as an asset acquisition of the Company’s net assets by Avant and a recapitalization of Avant as the Company did not meet the definition of a business under the framework provided under ASC 805-10-55-5D through 55-6 - Business Combination The cost of the Asset Sale Transaction was determined in accordance with ASC 805-50-30-1 through 30-2 Business Combinations In accordance with ASC 805-50-30-1, the fair value of the 1,000 shares of Series D-1 Preferred Stock, issued as consideration, was determined to be $246,656 which was the fair value of the Company’s net assets that were acquired by Avant as of the closing date of the transaction. The cost of the Asset Sale Transaction was allocated to the acquired assets and assumed liabilities based on their estimated fair values. The following assets and liabilities were assumed in the transaction: Cash $ 675,928 Prepaid expense and other current assets 17,539 Total assets acquired 693,467 Accounts payable and other liabilities (40,149 ) Liabilities of discontinued operations (406,662 ) Total liabilities assumed (446,811 ) Net assets acquired $ 246,656

Marketable Securities

Marketable Securities	9 Months Ended
	Jun. 30, 2020
Investments, Debt and Equity Securities [Abstract]
Marketable Securities	NOTE 4 – MARKETABLE SECURITIES During the fiscal year ended 2017, the Company acquired 1,000,000 shares of common stock of Amarantus BioScience Holdings, Inc. (“AMBS”) with a fair value of $40,980. The AMBS common stock is recorded as marketable securities in the accompanying balance sheets and its fair value is adjusted every reporting period and the change in fair value is recorded in the statements of operations as unrealized gain or (loss) on investments. During the nine and three months ended June 30, 2020, the Company recorded $11,200 and $4,900, respectively, of unrealized loss. As of June 30, 2020 and September 30, 2019, the fair value of these shares were $6,800 and $18,000, respectively.

Property and Equipment

Property and Equipment	9 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Property and Equipment	NOTE 5 – PROPERTY AND EQUIPMENT Property and equipment are recorded at cost and once placed in service, are depreciated on the straight-line method over their estimated useful lives. Leasehold improvements are accreted over the shorter of the estimated economic life or related lease terms. Fixed assets consist of the following: Estimated Useful Life in Years June 30, 2020 September 30, 2019 (Unaudited) Laboratory equipment 5 $ 397,432 $ 103,247 Furniture 5 13,367 — Leasehold improvements 5 330,309 216,984 Computer equipment 3 51,503 1,329 792,611 321,560 Less accumulated depreciation (45,556 ) (22,650 ) Property and equipment, net $ 747,055 $ 298,910 For the three and nine months ended June 30, 2020, depreciation expense related to property and equipment amounted to $9,675 and $22,906, respectively.

Loans Payable

Loans Payable	9 Months Ended
	Jun. 30, 2020
Debt Disclosure [Abstract]
Loans Payable	NOTE 6 – LOANS PAYABLE In September 2017, the Company entered into a loan agreement with a third-party investor (the “Loan”). Pursuant to the loan agreement, the Company borrowed the principal amount of $1,000. The Loan bears an annual interest rate of 33.3%, is unsecured and in default due to non-payment of the balance pursuant to the repayment terms. As of June 30, 2020, the loan had principal and accrued interest balances of $1,000 and $938, respectively.

Lease Liabilities

Lease Liabilities	9 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Lease Liabilities	NOTE 7 – LEASE LIABILITIES Financing Lease Payable Effective November 2018, the Company entered into a financing agreement with the first lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make monthly payment of $379 for a period of 60 months commencing in November 2018 through October 2023. At the effective date of the financing agreement, the Company recorded a financing lease payable of $16,064. Effective November 2018, the Company entered into a financing agreement with the second lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make monthly payment of $1,439 for a period of 60 months commencing in November 2018 through October 2023. At the effective date of the financing agreement, the Company recorded a financing lease payable of $62,394. Effective March 2019, the Company entered into a financing agreement with the third lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make monthly payment of $1,496 for a period of 60 months commencing in March 2019 through April 2024. At the effective date of the financing agreement, the Company recorded a financing lease payable of $64,940. Effective August 2019, the Company entered into a financing agreement with the fourth lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make monthly payment of $397 for a period of 60 months commencing in August 2019 through August 2024. At the effective date of the financing agreement, the Company recorded a financing lease payable of $19,622. Effective January 2020, the Company entered into a financing agreement with the fifth lessor to finance the purchase of equipment. Pursuant to the financing agreement, the Company shall make monthly payment of $1,395 for a period of 60 months commencing in January 2020 through December 2024. At the effective date of the financing agreement, the Company recorded a financing lease payable of $68,821. The significant assumption used to determine the present value of the financing lease payables was the discount rate which ranged from between 8% and 15% based on the Company’s estimated effective rate pursuant to the financing agreements. Financing lease right-of-use asset (“Financing ROU”) is summarized below: June 30, 2020 (Unaudited) Financing ROU asset $ 231,841 Less accumulated depreciation (61,936 ) Balance of Financing ROU asset as of June 30, 2020 $ 169,905 For the three and nine months ended June 30, 2020, depreciation expense related to Financing ROU asset amounted to $11,788 and $34,154, respectively. Financing lease liability related to the Financing ROU asset is summarized below: June 30, 2020 (Unaudited) Financing lease payables for equipment $ 231,841 Total financing lease payables 231,841 Payments of financing lease liabilities (43,710 ) Total 188,131 Less: short term portion as of June 30, 2020 (40,969 ) Long term portion as of June 30, 2020 $ 147,162 Future minimum lease payments under the financing lease agreements at June 30, 2020 are as follows: Years ending September 30, Amount 2020 $ 16,452 2021 61,266 2022 61,266 2023 53,787 2024 40,875 2025 4,185 Total minimum financing lease payments 237,831 Less: discount to fair value (49,700 ) Total financing lease payable at June 30, 2020 $ 188,131 Operating Lease Right-of-Use (“ROU”) Assets and Operating Lease Liabilities In December 2019, the Company entered into a lease agreement for its corporate and laboratory facility in Golden, Colorado. The lease is for a period of 60 months commencing in February 2020 and expiring in February 2025. Pursuant to the lease agreement, the lease requires the Company to pay a monthly base rent of; (i) $4,878 in the first year; (ii) $5,026 in the second year; (iii) $5,179 in the third year; (iv) $5,335 in the fourth year and; (v) $5,495 in the fifth year, plus a pro rata share of operating expenses beginning February 2020. In adopting ASC Topic 842, Leases (Topic 842), the Company has elected the ‘package of practical expedients’, which permit it not to reassess under the new standard its prior conclusions about lease identification, lease classification and initial direct costs (see Note 2). In addition, the Company elected not to apply ASC Topic 842 to arrangements with lease terms of 12 month or less. At the effective date of the lease, the Company recorded right-of-use assets and lease liabilities of $231,337. For the nine months ended June 30, 2020, lease costs amounted to $19,513 which included base lease costs of $10,414 and other expenses of $9,099, all of which were expensed during the period and included in general and administrative expenses on the accompanying condensed consolidated statements of operations. The significant assumption used to determine the present value of the lease liability was a discount rate of 12% which was based on the Company’s estimated incremental borrowing rate. Right-of-use asset (“ROU”) is summarized below: June 30, 2020 (Unaudited) Operating office lease $ 231,337 Less accumulated reduction (16,389 ) Balance of ROU asset as of June 30, 2020 $ 214,948 Operating lease liability related to the ROU asset is summarized below: June 30, 2020 (Unaudited) Operating office lease $ 231,337 Total lease liabilities 231,337 Reduction of lease liability (10,414 ) Total 220,923 Less: short term portion as of June 30, 2020 (34,450 ) Long term portion as of June 30, 2020 $ 186,473 Future base lease payments under the non-cancelable operating lease at June 30, 2020 are as follows: Years ending September 30, Amount 2020 $ 14,634 2021 59,576 2022 61,382 2023 63,236 2024 65,137 2025 27,474 Total minimum non-cancelable operating lease payments 291,439 Less: discount to fair value (70,516 ) Total lease liability at June 30, 2020 $ 220,923

Related-Party Transactions

Related-Party Transactions	9 Months Ended
	Jun. 30, 2020
Related Party Transactions [Abstract]
Related-Party Transactions	NOTE 8 – RELATED-PARTY TRANSACTIONS   Andrew Kucharchuk Consulting Agreement On June 5, 2020, the Company entered into a consulting agreement with Mr. Kucharchuk, a member of the Board of Directors, to serve as a strategic advisor to the Company’s Chief Executive Officer. The agreement shall be effective for a period of six-months, commencing on June 5, 2020 (see Note 3). Thereafter, the agreement shall only renew on a month-to-month basis by mutual agreement of the parties. Pursuant to the agreement, Mr. Kucharchuk shall receive compensation in the amount of $15,000 per month. The agreement was terminated subsequent to June 30, 2020.

Stockholders' Deficit

Stockholders' Deficit	9 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Stockholders' Deficit	NOTE 9 – STOCKHOLDERS’ DEFICIT Shares Authorized On September 22, 2020, the Company filed with the Nevada Secretary of State an amendment to its Certificate of Incorporation to change its name from “OncBioMune Pharmaceutical, Inc.” to “Theralink Technologies, Inc.” and increase its authorized shares of common stock from 6,666,667 shares of common stock at $0.0001 per share par value to 12,000,000,000 shares of common stock at $0.0001 per share par value, effective September 24, 2020 (see Note 1 and Note 11). The change in authorize shares has been retroactively reflected in the accompanying consolidated balance sheets. Series A Preferred Stock On August 20, 2015, the Company filed the Certificate of Designation with the Nevada Secretary of State, designating 1,333 shares of the authorized 26,667 Preferred Stock as Series A Preferred Stock. Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action. On June 5, 2020, pursuant to the asset sale transaction and recapitalization (see Note 3), 667 shares of Series A were deemed to have been issued. As of June 30, 2020, there were 667 shares of the Company’s Series A Preferred Stock issued and outstanding held by a former member of the Board of Directors. Series B Preferred Stock On March 7, 2017, the Company filed a Certificate of Designation, Preferences and Rights of Series B Preferred Stock (the “Series B Certificate of Designation”) with the Nevada Secretary of State to designate 10,523 shares of its previously authorized preferred stock as Series B Preferred Stock, par value $0.0001 per share and a stated value of $0.0001 per share. The Series B Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series B Preferred Stock were entitled to dividends or distributions share for share with the holders of the common stock, if, as and when declared from time to time by the Board of Directors. On June 11, 2020, the Company filed a Certificate of Withdrawal of Designation with the Nevada Secretary of State terminating the designation, amount thereof, voting powers, preferences and relative participating, optional and other special rights of the shares of the preferred stock of the Company designated as Series B Preferred Stock (see Note 1). As of June 30, 2020, there were no shares of the Company’s Series B Preferred Stock issued and outstanding. Series C-1 Preferred Stock On May 18, 2020, the Company filed a certificate of designation, preferences and rights of Series C-1 Preferred Stock (the “Series C-1 Certificate of Designation”), as amended on June 9, 2021, with the Nevada Secretary of State to designate 3,000 shares of its previously authorized preferred stock as Series C-1 Preferred Stock, par value $0.0001 per share and a stated value of $4,128.42 per share. The Series C-1 Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series C-1 Preferred Stock have the following preferences and rights: ● Holders of shares of Series C-1 Preferred Stock are entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors. ● Each share of Series C-1 Preferred Stock is convertible into shares of common stock any time after the Initial Issuance Date at a conversion price of $0.0275 per share. The number of shares of common stock issuable upon conversion shall be determined by dividing (x) (y) ● In the event the Company issues or sells any securities including options or convertible securities, except for any Exempt Issuance (as defined in the Series C-1 Certificate of Designation), at a price of or with an exercise price or conversion price of less than $0.00275 per share, then upon such issuance or sale, the Series C-1 Preferred Stock conversion price shall be reduced to the sale price, the exercise price or conversion price of the securities sold. In addition, these preferred shareholders have the right to participate in future equity offerings from the company for twenty four months from the effective date. ● In the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up of the Company, the holders of the Series C-1 Preferred Stock shall be entitled to receive, in cash out of the assets of the Company, whether from capital or from earnings available for distribution to its stockholders (“Liquidation Funds”) before any amount shall be paid to the holders of any shares of Junior Stock, but pari passu with any Parity Stock (as defined in the Series C-1 Certificate of Designation) then outstanding, an amount per shares of the Series C-1 Preferred Stock equal to the greater of (A) the conversion amount thereof on the date of such payment or (B) the amount per share such holder of Series C-1 Preferred Stock would receive if such holder converted such Series C-1 into common stock immediately prior to the date of the payment, provided that if the Liquidation Funds are insufficient to pay the full amount due to the holders of Series C-1 Preferred Stock and holders of the shares of Parity Stock, then each holder of Series C-1 Preferred Stock and each holder of Parity Stock shall receive a percentage of the Liquidation Funds equal to the full amount of the Liquidation Funds payable to such holder of Series C-1 Preferred Stock and such holder of the Parity Stock as a liquidation preference, in accordance with their respective certificate of designation (or equivalent), as a percentage of the full amount of Liquidation Funds payable to all holders of Series C-1 Preferred Stock and all holders of Parity Stock. On June 5, 2020, pursuant to the asset sale and recapitalization transaction (see Note 3), 2,966.2212 shares of Series C-1 Preferred Stock was deemed to have been issued. As of June 30, 2020, the Company had 2,966.2212 shares of Series C-1 Preferred Stock issued and outstanding. Series C-2 Preferred Stock On May 18, 2020, the Company filed a certificate of designation, preferences and rights of Series C-2 Preferred Stock (the “Series C-2 Certificate of Designation”) with the Nevada Secretary of State to designate 6,000 shares of its previously authorized preferred stock as Series C-2 Preferred Stock, par value $0.0001 per share and a stated value of $410.27 per share. The Series C-2 Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series C-2 Preferred Stock have the following preferences and rights: ● Holders of shares of Series C-2 Preferred Stock are entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors. ● Each share of Series C-2 Preferred Stock is convertible into shares of common stock any time after the initial issuance date at a conversion price of $0.00275 per share. The number of shares of common stock issuable upon conversion shall be determined by dividing (x) (y) ● In the event the Company issues or sells any securities including options or convertible securities, except for any Exempt Issuance (as defined in the Series C-2 Certificate of Designation), at a price of or with an exercise price or conversion price of less than the conversion price, then upon such issuance or sale, the Series C-2 Preferred Stock conversion price shall be reduced to the sale price, the exercise price or conversion price of the securities sold. In addition, these preferred shareholders have the right to participate in future equity offerings from the company for twenty four months from the effective date. ● In the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up of the Company, the holders of the Series C-2 Preferred Stock shall be entitled to receive, in cash out of the Liquidation Funds before any amount shall be paid to the holders of any shares of Junior Stock, but pari passu with any Parity Stock (as defined in the Series C-2 Certificate of Designation) then outstanding, an amount per shares of the Series C-2 Preferred Stock equal to the greater of (A) the conversion amount thereof on the date of such payment or (B) the amount per share such holder would receive if such holder converted such Series C-2 into common stock immediately prior to the date of the payment, provided that if the Liquidation Funds are insufficient to pay the full amount due to the holders of Series C-2 Preferred Stock and holders of the shares of Parity Stock, then each holder of Series C-2 Preferred Stock and each holder of Parity Stock shall receive a percentage of the Liquidation Funds equal to the full amount of the Liquidation Funds payable to such holder of Series C-2 Preferred Stock and such holder of the Parity Stock as a liquidation preference, in accordance with their respective certificate of designation (or equivalent), as a percentage of the full amount of Liquidation Funds payable to all holders of Series C-2 Preferred Stock and all holders of Parity Stock. On June 5, 2020, pursuant to the asset sale and recapitalization transaction (see Note 3), 4,916.865 shares of Series C-2 Preferred Stock was deemed to have been issued. As of June 30, 2020, the Company had 4,916.865 shares of Series C-2 Preferred Stock issued and outstanding. Series D-1 Preferred Stock On May 18, 2020, the Company filed a certificate of designation, preferences and rights of Series D-1 Preferred Stock (the “Series D-1 Certificate of Designation”) with the Nevada Secretary of State to designate 1,000 shares of its previously authorized preferred stock as Series D-1 Preferred Stock, par value $0.0001 per share and a stated value of $9,104.89 per share. The Series D-1 Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series D-1 Preferred Stock had the following preferences and rights: ● Holders of shares of Series D-1 Preferred Stock were entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors. ● Each share of Series D-1 Preferred Stock is convertible into a pro rata portion of 54 . 55% of the Fully Diluted Equity (as defined in the Series D-1 Certificate of Designation) of the Company ( the “Conversion Date”). ● Prior to the Conversion Date, each holder of Series D-1 Preferred Stock was entitled to the whole number of votes equal to the number of shares of common stock into which such holder’s Series D-1 vote or consent of stockholders, and otherwise had voting rights and powers equal to the voting rights and powers of the common stock. To the extent that under the Nevada Revised Statutes (“NRS”) the vote of the holders of the Series D-1, voting separately as a class or series as applicable, was required to authorize a given action, the affirmative vote or consent of the holders of a majority of the shares of the outstanding Series D-1, constituted the approval of such action by both the class or the series, as applicable (except as otherwise may be required under the NRS). For the nine months ended 6/30/20, the Company issued an aggregate of 1 share of D-1 Preferred Stock in exchange for the settlement of certain accrued compensation and the conversion of debt valued at $676,369. For the nine months ended 6/30/20, the company sold 7 shares of D-1 Preferred Stock for net proceeds of $2,590,000. As of June 30, 2020, the Company had 1,000 shares of Series D-1 Preferred Stock issued and outstanding, all of which were converted into 5,081,549,184 shares of common stock subsequent to June 30, 2020. Series D-2 Preferred Stock On May 18, 2020, the Company filed a certificate of designation, preferences and rights of Series D-2 Preferred Stock (the “Series D-2 Certificate of Designation”) with the Secretary of State of the State of Nevada to designate 4,360 shares of its previously authorized preferred stock as Series D-2 Preferred Stock, par value $0.0001 per share and a stated value of $500 per share. The Series D-2 Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law. The holders of shares of Series D-2 Preferred Stock have the following preferences and rights: ● Holders of shares of Series D-2 Preferred Stock are entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors. ● Each share of Series D-2 Preferred Stock are convertible into 10,000 shares of common stock (“Conversion Rate”). Upon the terms and in the manner set forth in Section 5 of the Series D-2 Certificate of Designation, each outstanding share of the Series D-2 Preferred Stock shall automatically be converted upon the effectiveness of the amendment to the Company’s Articles of Incorporation to increase the Company’s authorized common stock, par value $0.0001 per share, from 6,666,667 shares to 12,000,000,000 shares, which occurred on September 24, 2020 ( the “Conversion Date”)., into a number of fully-paid and nonassessable shares of Common Stock determined by multiplying such share of Series D-2 Preferred Stock by the Conversion Rate (such shares of Common Stock issuable upon Conversion, the “Conversion Shares”). ● Each holder of Series D-2 Preferred Stock shall be entitled to the whole number of votes equal to the number of shares of common stock into which such holder’s Series D-2 would be convertible on the record date for the vote or consent of stockholders and shall otherwise have voting rights and powers equal to the voting rights and powers of common stock. To the extent that under the NRS the vote of the holders of the Series D-2 , voting separately as a class or series as applicable , is required to authorize a given action of the Corporation , the affirmative vote or consent of the holders of a majority of the shares of the outstanding Series D-2 , shall constitute the approval of such action by both the class or the series , as applicable (except as otherwise may be required under the NRS). ● In the event of the voluntary or involuntary liquidation, dissolution, distribution of assets or winding-up of the Company, the holders of the Series D-2 Preferred Stock shall be entitled to receive, in cash out of the assets of the Company, whether from capital or from earnings available for distribution to its stockholders (“Liquidation Funds”) before any amount shall be paid to the holders of any shares of Junior Stock, but pari passu with any Parity Stock (as defined in the Certificate of Designation) then outstanding , an amount per shares of the Series D-2 Preferred Stock equal to the greater of (A) the Conversion Amount thereof on the date of such payment or (B) the amount per share such Holder would receive if such Holder converted such Series D-2 into common stock immediately prior to the date of the payment, provided that if the Liquidation Funds are insufficient to pay the full amount due to the Holders and holders of the shares of Parity Stock, then each Holder and each holder of Parity Stock shall receive a percentage of the Liquidation Funds equal to the full amount of the Liquidation Funds payable to such Holder and such holder of the Parity Stock as a liquidation preference, in accordance with their respective certificate of designation (or equivalent), as a percentage of the full amount of Liquidation Funds payable to all holders of Series D-2 Preferred Stock and all holders of Parity Stock. On June 5, 2020, the Company is deemed to have issued 4,121.64 shares of Series D-2 Preferred Stock pursuant to the Asset Sale Transaction and recapitalization. As of June 30, 2020, the Company had 4,121.64 shares of Series D-2 Preferred Stock issued and outstanding, all of which were converted into 41,216,450 shares of common stock, subsequent to June 30, 2020. Common Stock On June 5, 2020, the Company is deemed to have issued 1,398,070 shares of common stock pursuant to the Asset Sale Transaction and recapitalization. As of June 30, 2020, the Company had 1,398,070 shares of common stock issued and outstanding. Warrants In November 2019, in connect with the sale of series D-1 preferred stock, the Company issued certain warrants to a subscriber. On June 5, 2020, in connection with the Asset Sale Transaction and recapitalization, the company issued 656,674,588 new warrants to the same subscriber in exchange for the previously issued warrants. The new warrants are exercisable immediately at an exercise price of $0.00214 and expire on November 27, 2024. On June 5, 2020 in connection with the Asset Sale Transaction and the recapitalization transaction, the Company issued 200,000,000 warrants to two investors. The warrants are exercisable three-months after the grant date at an exercise price of $0.00214 and expires on five-years form the vest date. As of June 30, 2020, the Company had 856,674,588 warrants issued and outstanding. Warrants activities for the nine months ended June 30, 2020 is summarized as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Price Term (Years) Value Balance Outstanding at September 30, 2019 — $ — — $ — Warrants issued in connection with the sale of Series D-1 preferred stock 656,674,588 0.002 4.41 — Deemed issuance in connection with the asset sale and recapitalization transaction (see Note 3) 200,000,000 0.003 5.19 — Balance Outstanding at June 30, 2020 856,674,588 $ 0.002 4.59 $ — Exercisable at June 30, 2020 656,674,588 $ 0.002 4.41 $ — Stock options Effective February 18, 2011, the Company’s Board of Directors (“Board”) adopted and approved the 2011 stock option plan. A total of 57 options to acquire shares of the Company’s common stock were authorized under the 2011 stock option plan and during the twelve-month period after the first anniversary of the adoption of the 2011 stock option plan, the Company’s board of directors and during each twelve-month period thereafter, our board of directors is authorized to increase the number of options authorized under this plan by up to 14 shares. No options were granted under the 2011 stock option plan as of June 30, 2020. On April 28, 2020, the Board approved the 2020 Equity Incentive Plan (the “Plan”), as amended on May 29, 2020. The Plan shall be effective upon approval by the Stockholders which shall be within twelve (12) months after the approval of the Board. No Incentive Stock Option shall be exercised unless and until the Plan has been approved by the Stockholders. Upon the effective date of the Plan and the effectiveness of the authorized share increase, which occurred on September 24, 2020, 3,043,638,781 shares of the Company’s common stock were be reserved for issuance under the Plan (the “Reserved Share Amount”), subject to the adjustments described in the Plan, and such Reserved Share Amount, when issued in accordance with the Plan, shall be validly issued, fully paid, and non-assessable. Pursuant to the Plan, the option price of each incentive stock option (except those that constitute substitute awards under the Plan) shall be at least the fair market value of a share of common stock on the respective grant date; provided, however, that in the event that a grantee is a ten-percent stockholder as of the grant date, the option price of an incentive stock option shall be not less than 110% of the fair market value of a share on the grant date. The stock option plan has not yet been approved by the shareholders. As of June 30, 2020, the Company had no options issued and outstanding.

Commitment and Contingencies

Commitment and Contingencies	9 Months Ended
	Jun. 30, 2020
Commitments and Contingencies Disclosure [Abstract]
Commitment and Contingencies	NOTE 10 – COMMITMENT AND CONTINGENCIES Employment Agreements Michael Ruxin, M.D. On June 5, 2020, the Company and Dr. Michael Ruxin. entered into an employment agreement (the “Ruxin Employment Agreement”) for Dr. Ruxin to serve as the Company’s Chief Executive Officer, President and a director (see Note 3). The Ruxin Employment Agreement provides that Dr. Ruxin will be employed for a five-year term commencing on June 5, 2020, automatically extended for one additional year upon the fifth anniversary of the effective date without any affirmative action, unless either party to the agreement provides at least sixty (60) days’ advance written notice to the other party that the employment period will not be extended. Dr. Ruxin will be entitled to receive an annual base salary of $300,000 and will be eligible for an annual discretionary bonus of 150% of such base salary. In the Ruxin Employment Agreement, Dr. Ruxin is also promised, subject to the approval of the Board or a committee thereof, and under the 2020 Equity Incentive Plan (i) a one-time grant of 49,047,059 Restricted Stock Units (“RSUs”) and (ii) a one-time grant of options to purchase 420,691,653 shares of Common Stock, both of which will be subject to the terms and conditions of the applicable award agreement when executed. Dr. Ruxin is entitled to participate in any and all benefit plans, from time to time, in effect for senior management, along with vacation, sick and holiday pay in accordance with the Company’s policies established and in effect from time to time. As of June 30, 2020, the RSUs and options have not yet been granted or issued since the Board has not yet approved the grants and the Equity Incentive Plan has not been approved by the shareholders. Dr. Ruxin is an “at-will” employee and his employment may be terminated by the Company at any time, with or without cause. In the event Dr. Ruxin’s termination of employment is the result of termination by the Company without Cause (as defined in the Ruxin Agreement), with Good Reason (as defined in the Ruxin Agreement) or as a result of a non-renewal of the term of employment under the Ruxin Agreement, Dr. Ruxin shall be entitled to receive the sum of (I) the Severance Multiple (as defined below), multiplied by multiplied by provided, however The Ruxin Agreement also contains covenants (a) restricting the executive from engaging in any activity competitive with our business during the term of the employment agreement and in the event of termination, for a period of one year thereafter, (b) prohibiting the executive from disclosing confidential information regarding the Company, and (c) soliciting employees, customers and prospective customers during the term of the employment agreement and for a period of one year thereafter. Jeffrey Busch On June 5, 2020, the Company and Jeffrey Busch entered into an employment agreement (the “Busch Employment Agreement”) for Mr. Busch to serve as the Company’s Chairman of the Board of Directors (see Note 3). The Busch Employment Agreement provides that Mr. Busch will be employed for a five-year term commencing on June 5, 2020, automatically extended for one additional year upon the fifth anniversary of the effective date without any affirmative action, unless either party to the agreement provides at least sixty (60) days’ advance written notice to the other party that the employment period will not be extended. Mr. Busch will be entitled to receive an annual base salary of $60,000 and will be eligible for an annual discretionary bonus. In the Busch Employment Agreement, Mr. Busch is also promised, subject to the approval of the Board or committee thereof, and under the 2020 Equity Incentive Plan (i) a one-time grant of 49,047,059 Restricted Stock (“RSUs”) and (ii) a one-time grant of options to purchase 420,691,653 shares of Common Stock, both of which will be subject to the terms and conditions of the applicable award agreement when executed. Mr. Busch is entitled to participate in any and all benefit plans, from time to time, in effect for senior management, along with vacation, sick and holiday pay in accordance with the Company’s policies established and in effect from time to time. As of June 30, 2020, the RSUs and options have not yet been granted or issued since the Board has not yet approved the grants and the Equity Incentive Plan has not been approved by the shareholders. Mr. Busch is an “at-will” employee and his employment may be terminated by the Company at any time, with or without cause. In the event Mr. Busch’s termination of employment is the result of termination by the Company without Cause (as defined in the Busch Agreement), with Good Reason (as defined in the Busch Agreement) or as a result of a non-renewal of the term of employment under the Busch Agreement, Mr. Busch shall be entitled to receive the sum of (I) the Severance Multiple (as defined below), multiplied by multiplied by provided, however The Busch Agreement also contains covenants (a) restricting the executive from engaging in any activity competitive with our business during the term of the employment agreement and in the event of termination, for a period of one year thereafter, (b) prohibiting the executive from disclosing confidential information regarding the Company, and (c) soliciting employees, customers and prospective customers during the term of the employment agreement and for a period of one year thereafter. Lease In December 2019, the Company entered into a lease agreement its corporate and laboratory facility in Golden, Colorado. The lease is for a period of 60 months commencing in February 2020 and expiring in February 2025 (see Note 7). Other Contingencies On June 5, 2020, the Company recorded a contingent liability of $62,240 resulting from certain liabilities of Avant prior to the asset sale and recapitalization transaction (see Note 3). Pursuant to ASC 450-20 - Loss Contingencies, liabilities for contingencies arising from claims, assessments, litigation, fines and penalties and other sources are recorded when it is probable that a liability has been incurred and the amount of the assessment can be reasonably estimated.

Subsequent Events

Subsequent Events	9 Months Ended
	Jun. 30, 2020
Subsequent Events [Abstract]
Subsequent Events	NOTE 11 – SUBSEQUENT EVENTS On August 14, 2020, the Board approved a change in the Company’s fiscal year end from December 31 to September 30, effective immediately for the current fiscal year, and for all subsequent years until such time as the Board resolves to amend such fiscal year end. The fiscal year has been changed to conform to the September 30 fiscal year end of Avant which is the historical registrant as a result of the Asset Sale Transaction consummated on June 5, 2020 and therefore, no transition report is required (see Note 1). On September 15, 2020, the Company filed a certificate of designation, preferences and rights of Series E Preferred Stock (the “Series E Certificate of Designation”) with the Nevada Secretary of the State to designate 2,000 shares of its previously authorized preferred stock as Series E Preferred Stock, par value $0.0001 per share and a stated value of $2,000 per share. The Series E Certificate of Designation and its filing was approved by the Company’s board of directors without shareholder approval as provided for in the Company’s articles of incorporation and under Nevada law (see Note 1). The holders of shares of Series E Preferred Stock have the following preferences and rights: ● From the initial issuance date, cumulative dividends on each share of Series E shall accrue, on a quarterly basis in arrears (with any partial quarter calculated on a pro-rata basis), at the rate of 8% per annum on the Stated Value, plus any additional amount thereon. Dividends shall be paid within 15 days after the end of each fiscal quarter (“Dividend Payment Date”), at the option of the Holder in cash or through the issuance of shares of common stock. In the event that the Holder elects to receive its dividends in shares of common stock the number of shares of common stock to be issued to each applicable Holder shall be determined by dividing the total dividend outstanding to such Holder by the average closing price of the common stock during the five trading days on the principal market prior to the Dividend Payment Date. ● Holders of shares of Series E Preferred Stock are entitled to dividends or distributions on each share on an “as converted” into common stock basis, if, as and when declared from time to time by the Board of Directors. ● Each share of Series E Preferred Stock is convertible into shares of common stock any time after the initial issuance date at the Conversion Price which is the lesser of: (i) $0.00375 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principal market, subject to adjustment as provided in the Series E Certificate of Designation. Provided, however, the Conversion Price shall never be less than $0.0021. The number of shares of common stock issuable upon conversion shall be determined by multiplying the number of outstanding shares by the stated value per share of $2,000 plus accrued dividends and dividing that number by (y) ● In connection with, (i) a Change of Control of the Corporation or (ii) on the closing of, a Qualified Public Offering by the Corporation, all of the outstanding shares of Series E (including any fraction of a share) shall automatically convert into an aggregate number of shares of Common Stock (including any fraction of a share) by multiplying the number of outstanding shares by the stated value per share of $2,000 plus accrued dividends and dividing that number (including any fraction of a share) by the lesser of: (i) $0.00375 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principle market. However, the conversion price shall never be less than $0.0021. If a closing of a Change of Control transaction or a Qualified Public Offering occurs, such automatic conversion of all of the outstanding shares of Series E shall be deemed to have been converted into shares of Common Stock immediately prior to the closing of such transaction or Qualified Public Offering. ● In the event the Company issues or sells any securities including options or convertible securities, except for any Exempt Issuance (as defined in the Series E Certificate of Designation), at a price, an exercise price or conversion price of less than the conversion price, then upon such issuance or sale, the Series E Preferred Stock conversion price shall be reduced to the sale price or the exercise price or conversion price of the securities sold. ● Holder of Series E Preferred Stock have no voting rights. On September 16, 2020, the Company entered into a Securities Purchase Agreement (the “SPA”) with an investor to purchase an aggregate amount of 1,000 shares of the newly created Series E Convertible Preferred Stock of the Company (the “Series E Preferred”) for an aggregate investment amount of $2,000,000. The Company’s Series E Preferred Stock has a stated value of $2,000 per share and shall accrue, on a quarterly basis in arrears, dividends at the rate of 8% per annum on the stated value. The dividends shall be paid quarterly at the option of the holder of the Series E Preferred in either cash or shares of common stock of the Company. The Series E Preferred is convertible at any time after the date that is two days after the filing of an amendment to the Company’s certificate of incorporation with the Nevada Secretary of State to increase the Company’s authorized common stock to 12,000,000,000 which became effective on September 24, 2020. The number of shares of common stock issuable on the conversion of the Series E Preferred is determined by dividing the stated value of the number of shares being converted, plus any accrued and unpaid dividends, by the lesser of: (i) $0.00375 and (ii) 75% of the average closing price of the Company’s common stock during the prior five trading days; provided, however, the conversion price shall never be less than $0.0021. For eighteen months from the anniversary of the closing, the Company needs to obtain consent from a group of investors prior to engaging in any future capital raises. On September 22, 2020, the Company filed with the Nevada Secretary of State an amendment to its Certificate of Incorporation to change its name from “OncBioMune Pharmaceutical, Inc.” to “Theralink Technologies, Inc.” and increase its authorized shares of common stock from 6,666,667 shares of common stock at $0.0001 per share par value to 12,000,000,000 shares of common stock at $0.0001 per share par value, effective September 24, 2020 (see Note 1 and Note 9). The 1,000 shares of Series D-1 Preferred stock and 4,121.6 shares of Series D-2 Preferred stock were automatically converted into 5,081,549,184 and 41,216,000 shares of common stock, respectively, upon the increase in the authorized shares, pursuant to the respective Certificates of Designation (see Note 1). On September 24, 2020, the Company appointed Thomas E. Chilcott, III, to serve as the Chief Financial Officer. The Company entered into an offer letter with Mr. Chilcott which provides that his base salary will be $225,000 per year and that he will be eligible to receive the following bonuses: $5,000 if the Company’s next Annual Report on Form 10-K is filed on or prior to December 12, 2020; $5,000 if the Company files a registration statement on Form S-1 on or prior to January 15, 2021; $5,000 if the Company completes a capital raise of at least $3,000,000 on or prior to Apri1 15, 2021; $20,000 if the Company completes a capital raise of at least $10,000,000 on or prior to September 30, 2021; and $15,000 if the Company successfully lists on a Nasdaq stock market on or before December 31, 2021. Mr. Chilcott is entitled to participate in all medical and other benefits that the Company has established for its employees. The offer letter also provides that Mr. Chilcott will be granted an option to purchase up to 94,545,096 shares of the Company’s common stock subject to terms including exercise price to be set by the Board of Directors of the Company (see Note 1). From February 16, 2021 through April 14, 2021, the Company, entered into Subscription Agreements with fourteen accredited investors to sell, in a private placements, an aggregate of 431,309,904 shares of its common stock, par value $0.0001 per share, at a purchase price of $0.00313 per share for an aggregate purchase price of $1,350,000. The Shares sold by the Company under these Subscription Agreements were in reliance upon an exemption from the registration requirements of the Act afforded by Section 4(a)(2) of the Act and/or Rule 506 of Regulation D thereunder. The private placements were made directly by the Company and no underwriter or placement agent was engaged by the Company. The Company did not engage in general solicitation or advertising and did not offer securities to the public in connection with this offering. On May 12, 2021, the Company entered into a Securities Purchase Agreement (the “SPA”) with an investor (the “Investor”) to purchase a convertible note (the “Note”) and accompanying warrant (the “Warrant”) for an aggregate investment amount of $1,000,000. The Note has a principal value of $1,000,000 and bears an interest rate of 8% per annum (which shall increase to 10% per year upon the occurrence of an “Event of Default” (as defined in the Note)) and shall mature on May 12, 2026 (the “Maturity Date”). The Note is convertible at any time into shares of the Company’s common stock at a conversion price equal to $0.00313 per share for any amount of principal and accrued interest remaining outstanding (subject to adjustment as provided therein). The Company may prepay the Note at any time in an amount equal to 110% of the outstanding principal balance and accrued interest. In connection with the Note, the Investor was issued a Warrant to purchase up to 63,897,764 shares of common stock at an exercise price of $0.00313 per share (subject to adjustment as provided therein) until May 12, 2026. The Warrants are exercisable for cash at any time. In connection with the Company’s obligations under the Note, the Company entered into a security agreement (the “Security Agreement”) with Ashton Capital Corporation as agent, pursuant to which the Company granted a lien on certain pieces of laboratory equipment of the Company (the “Collateral”), for the benefit of the Investor, to secure the Company’s obligations under the Note. Upon an Event of Default (as defined in the Notes), the Investor may, among other things, collect or take possession of the Collateral, proceed with the foreclosure of the security interest in the Collateral or sell, lease or dispose of the Collateral. On June 9, 2021, the Company filed an Amendment (the “CoD Amendment") to the Series C-1 Certificate of Designation with the Nevada Secretary of State. The filing of the CoD Amendment was approved by the Board on June 8, 2021, and by the holders of the majority of the outstanding shares of Series C-1 Preferred Stock on June 8, 2021. The CoD Amendment sets the triggering price for the anti-dilution price protection at $0.00275 per share, the same price as is in the Series C-2 Certificate of Designation. All other terms of the Series C-1 Certificate of Designation remain unchanged and in full force and effect. The foregoing description of the CoD Amendment is qualified in its entirety by reference to the CoD Amendment, a copy of which is attached to this Quarterly Report on Form 10-Q as Exhibit 3.3.

Summary of Significant Accoun_2

Summary of Significant Accounting Policies (Policies)	9 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Basis of Presentation and Principles of Consolidation	Basis of Presentation and Principles of Consolidation The accompanying interim condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America and the rules and regulations of the United States Securities and Exchange Commission (“SEC”) for interim financial information, which present the consolidated financial statements of the Company and its wholly-owned subsidiary as of June 30, 2020. All intercompany transactions and balances have been eliminated. On April 4, 2021, the Company filed with the SEC the audited restated financial statements of Avant for the fiscal year ended September 30, 2019 and related notes on Amendment No. 2 to its Current Report on Form 8-K/A. Accordingly, the interim audited condensed consolidated financial statements do not include all the information and notes necessary for a comprehensive presentation of financial position and results of operations and should be read in conjunction with the audited financial statements of Avant for the year ended September 30, 2019. It is management’s opinion that all material adjustments (consisting of normal recurring adjustments and non-recurring adjustments) have been made, which are necessary for a fair financial statement presentation. The results for the interim period are not necessarily indicative of the results to be expected for the year ending September 30, 2020. These interim condensed consolidated financial statements for the period ending June 30, 2020 consist of the interim condensed consolidated balance sheets of the Company as of June 30, 2020 and the related interim condensed consolidated statements of operations, changes in stockholders’ equity (deficit) and cash flows for the three and nine month periods ended June 30, 2020 and 2019, and the related notes, and reflect the acquisition of the Company’s net assets pursuant to the Asset Sale Transaction with Avant Diagnostics, Inc. and concurrent recapitalization, which was consummated on June 5, 2020, as more fully disclosed in Note 3.
Going Concern	Going Concern These consolidated financial statements have been prepared on a going concern basis, which contemplates the realization of assets and the settlement of liabilities and commitments in the normal course of business. As reflected in the accompanying condensed consolidated financial statements, the Company had net loss and net cash used in operations of $1,837,155 and $2,351,823, respectively, for the nine months ended June 30, 2020. Additionally, the Company had an accumulated deficit, stockholders’ equity and working capital of $39,848,356, $1,043,510 and $218,973 at June 30, 2020. Management believes that these matters raise substantial doubt about the Company’s ability to continue as a going concern for twelve months from the issuance date of this report. The Company cannot provide assurance that it will ultimately achieve profitable operations or become cash flow positive or raise additional debt or equity capital. Additionally, the current capital resources are not adequate to continue operating and maintaining the business strategy for a period of twelve months from the issuance date of this report. The Company will seek to raise capital through additional debt and equity financings to fund its operations in the future. Although the Company has historically raised capital from sales of equity and from the issuance of promissory notes, there is no assurance that it will be able to continue to do so. If the Company is unable to raise additional capital or secure additional lending in the near future, management expects that the Company will need to curtail or cease operations. These consolidated financial statements do not include any adjustments related to the recoverability and classification of recorded asset amounts and classification of liabilities that might be necessary should the Company be unable to continue as a going concern. The global pandemic COVID-19, otherwise referred to as the Coronavirus, could impair our ability to raise additional funding or make such funding more costly. The ongoing global pandemic has caused cessation of normal business operations and caused capital markets to decline sharply. This could make it more difficult for the Companies to access capital. It is currently difficult to estimate with any certainty how long the pandemic and resulting curtailment of business will continue, and its effect on capital markets and the Company’s ability to raise funds is, accordingly, difficult to quantify. In addition, to the extent that any of the Company’s personnel or consultants are affected by the virus, this could cause delays or disruption in our planned research and development activities.
Use of Estimates	Use of Estimates The preparation of consolidated financial statements in conformity with U.S. GAAP requires management to make judgments, assumptions, and estimates that affect the amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from these estimates. Management bases its estimates and assumptions on current facts, historical experience, and various other factors that it believes are reasonable under the circumstances, to determine the carrying values of assets and liabilities that are not readily apparent from other sources. Significant estimates during the nine months ended June 30, 2020 and year ended September 30, 2019 include, but are not necessarily limited to, the valuation of assets and liabilities of discontinued operations, estimates of contingent liabilities, valuation of marketable securities, useful life of property and equipment, valuation of right-of-use (“ROU”) assets and operating lease liabilities, assumptions used in assessing impairment of long-term assets, allowances for sales returns, estimates of current and deferred income taxes and deferred tax valuation allowances and the fair value of non-cash equity transactions. Additionally, the full impact of COVID-19 is unknown and cannot be reasonably estimated. However, the Company has made appropriate accounting estimates based on the facts and circumstances available as of the reporting date. To the extent there are material differences between the Company’s estimates and the actual results, the Company’s future consolidated results of operation will be affected.
Fair Value of Financial Instruments and Fair Value Measurements	Fair Value of Financial Instruments and Fair Value Measurements FASB ASC 820 - Fair Value Measurements and Disclosures, defines fair value as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. FASB ASC 820 requires disclosures about the fair value of all financial instruments, whether or not recognized, for financial statement purposes. Disclosures about the fair value of financial instruments are based on pertinent information available to the Company on June 30, 2020. Accordingly, the estimates presented in these financial statements are not necessarily indicative of the amounts that could be realized on disposition of the financial instruments. FASB ASC 820 specifies a hierarchy of valuation techniques based on whether the inputs to those valuation techniques are observable or unobservable. Observable inputs reflect market data obtained from independent sources, while unobservable inputs reflect market assumptions. The hierarchy gives the highest priority to unadjusted quoted prices in active markets for identical assets or liabilities (Level 1 measurement) and the lowest priority to unobservable inputs (Level 3 measurement). The three levels of the fair value hierarchy are as follows: Level 1—Inputs are unadjusted quoted prices in active markets for identical assets or liabilities available at the measurement date. Level 2—Inputs are unadjusted quoted prices for similar assets and liabilities in active markets, quoted prices for identical or similar assets and liabilities in markets that are not active, inputs other than quoted prices that are observable, and inputs derived from or corroborated by observable market data. Level 3—Inputs are unobservable inputs which reflect the reporting entity’s own assumptions on what assumptions the market participants would use in pricing the asset or liability based on the best available information. In August 2018, the FASB issued ASU 2018-13 —Fair Value Measurement (Topic 820): Disclosure Framework Changes to the Disclosure Requirements for Fair Value Measurement
Cash	Cash For purposes of the consolidated statements of cash flows, the Company considers all highly liquid instruments with a maturity of three months or less at the purchase date and money market accounts to be cash equivalents. At June 30, 2020 and September 30, 2019, the Company did not have any cash equivalents. The Company maintains its cash in banks and financial institutions that at times may exceed federally insured limits. There were cash balances in excess of FDIC insured levels as of June 30, 2020 and September 30, 2019. The Company has not experienced any losses in such accounts through June 30, 2020.
Property and Equipment	Property and Equipment Fixed assets are stated at cost and depreciated using the straight-line method over their estimated useful lives, which range from three to five years. Leasehold improvements are depreciated over the shorter of the useful life or lease term including scheduled renewal terms. Maintenance and repairs are charged to expense as incurred. When assets are retired or disposed of, the cost and accumulated depreciation are removed from the accounts, and any resulting gains or losses are included in income in the year of disposition. The Company examines the possibility of decreases in the value of these assets when events or changes in circumstances reflect the fact that their recorded value may not be recoverable.
Impairment of Long-lived Assets	Impairment of Long-Lived Assets In accordance with ASC Topic 360, the Company reviews long-lived assets for impairment whenever events or changes in circumstances indicate that the carrying amount of the assets may not be fully recoverable, or at least annually. The Company recognizes an impairment loss when the sum of expected undiscounted future cash flows is less than the carrying amount of the asset. The amount of impairment is measured as the difference between the asset’s estimated fair value and its book value.
Stock-based Compensation	Stock-Based Compensation Stock-based compensation is accounted for based on the requirements of the Share-Based Payment Topic of ASC 718 which requires recognition in the financial statements of the cost of employee and director services received in exchange for an award of equity instruments over the period the employee or director is required to perform the services in exchange for the award (presumptively, the vesting period). The ASC also requires measurement of the cost of employee and director services received in exchange for an award based on the grant-date fair value of the award. Pursuant to ASC 505-50 - Equity-Based Payments to Non-Employees, all share-based payments to non-employees, including grants of stock options, were recognized in the consolidated financial statements as compensation expense over the service period of the consulting arrangement or until performance conditions are expected to be met. Using a Black Scholes valuation model, the Company periodically reassessed the fair value of non-employee options until service conditions are met, which generally aligns with the vesting period of the options, and the Company adjusts the expense recognized in the consolidated financial statements accordingly. In June 2018, the FASB issued ASU No. 2018-07, Improvements to Nonemployee Share-Based Payment Accounting, which simplifies several aspects of the accounting for nonemployee share-based payment transactions by expanding the scope of the stock-based compensation guidance in ASC 718 to include share-based payment transactions for acquiring goods and services from non-employees. ASU No. 2018-07 is effective for annual periods beginning after December 15, 2018, including interim periods within those annual periods. Early adoption is permitted, but entities may not adopt prior to adopting the new revenue recognition guidance in ASC 606. The Company early adopted ASU No. 2018-07 during the period September 30, 2018, and the adoption did not have any impact on its consolidated financial statements.
Revenue Recognition	Revenue Recognition In May 2014, FASB issued an Accounting Standards Update, ASU 2014-09, establishing ASC 606 - Revenue from Contracts with Customers. ASU 2014-09, as amended by subsequent ASUs on the topic, establishes a single comprehensive model for entities to use in accounting for revenue arising from contracts with customers and supersedes most of the existing revenue recognition guidance. This standard, which is effective for interim and annual reporting periods in fiscal years that begin after December 15, 2017, requires an entity to recognize revenue to depict the transfer of promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled in exchange for those goods or services and also requires certain additional disclosures. The Company adopted this standard during the fiscal year ended September 30, 2018 using the modified retrospective approach, which requires applying the new standard to all existing contracts not yet completed as of the effective date and recording a cumulative-effect adjustment to retained earnings as of the beginning of the fiscal year of adoption. Based on an evaluation of the impact ASU 2014-09 will have on the Company’s sources of revenue, the Company has concluded that ASU 2014-09 did not have any impact on the process for, timing of, and presentation and disclosure of revenue recognition from customers and there was no cumulative effect adjustment. The Company had $24,886 and $75,896 of revenues from operations during the three and nine months ended June 30, 2020.
Cost of Revenue	Cost of Revenue The cost of revenue consists of the cost of labor, supplies and materials.
Accounts Receivable and Allowance for Doubtful Accounts	Accounts Receivable and Allowance for Doubtful Accounts Trade receivables are carried at their estimated collectible amounts. Trade credit is generally extended on a short-term basis and do not bear interest. Trade accounts receivable are periodically evaluated for collectability based on past credit history with customers and their current financial condition. Any charges to the allowance for doubtful accounts on accounts receivable are charged to operations in amounts sufficient to maintain the allowance for uncollectible accounts at a level management believes is adequate to cover any probable losses. Management determines the adequacy of the allowance based on historical write-off percentages and the current status of accounts receivable. Accounts receivable are charged off against the allowance when collectability is determined to be permanently impaired. The allowance for doubtful accounts was $0 at June 30, 2020 and September 30, 2019.
Basic and Diluted Loss Per Share	Basic and Diluted Loss Per Share Pursuant to ASC 260-10-45, basic loss per common share is computed by dividing net loss by the weighted average number of shares of common stock outstanding for the periods presented. Diluted loss per share is computed by dividing net loss by the weighted average number of shares of common stock, common stock equivalents and potentially dilutive securities outstanding during the period. Potentially dilutive common shares consist of common stock issuable for stock options and warrants (using the treasury stock method), convertible notes and common stock issuable. These common stock equivalents may be dilutive in the future. The following potentially dilutive equity securities outstanding as of June 30, 2020 and 2019 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive: June 30, 2020 2019 Stock warrants 856,674,588 — Series C-1 preferred stock 445,301,289 — Series C-2 preferred stock 733,542,619 — Series D-1 preferred stock 4,441,433,275 4,392,557,509 Series D-2 preferred stock 41,216,000 — 6,518,167,771 4,392,557,509
Income Taxes	Income Taxes The Company accounts for income tax using the liability method prescribed by ASC 740 - Income Taxes. Under this method, deferred tax assets and liabilities are determined based on the difference between the financial reporting and tax bases of assets and liabilities using enacted tax rates that will be in effect in the year in which the differences are expected to reverse. The Company records a valuation allowance to offset deferred tax assets if based on the weight of available evidence, it is more-likely-than-not that some portion, or all, of the deferred tax assets will not be realized. The effect on deferred taxes of a change in tax rates is recognized as income or loss in the period that includes the enactment date. The Company follows the accounting guidance for uncertainty in income taxes using the provisions of ASC 740 “Income Taxes
Related Parties	Related Parties Parties are considered to be related to the Company if the parties, directly or indirectly, through one or more intermediaries, control, are controlled by, or are under common control with the Company. Related parties also include principal owners of the Company, its management, members of the immediate families of principal owners of the Company and its management and other parties with which the Company may deal with if one party controls or can significantly influence the management or operating policies of the other to an extent that one of the transacting parties might be prevented from fully pursuing its own separate interests.
Leases	Leases In February 2016, the Financial Accounting Standards Board (“FASB”) issued ASU 2016-02, Leases On January 1, 2019, the Company adopted ASU No. 2016-02, applying the package of practical expedients to leases that commenced before the effective date whereby the Company elected to not reassess the following: (i) whether any expired or existing contracts contain leases and; (ii) initial direct costs for any existing leases. For contracts entered into on or after the effective date, at the inception of a contract the Company assessed whether the contract is, or contains, a lease. The Company’s assessment is based on: (1) whether the contract involves the use of a distinct identified asset, (2) whether we obtain the right to substantially all the economic benefit from the use of the asset throughout the period, and (3) whether it has the right to direct the use of the asset. The Company will allocate the consideration in the contract to each lease component based on its relative stand-alone price to determine the lease payments. The Company has elected not to recognize right-of-use (“ROU”) assets and lease liabilities for short-term leases that have a term of 12 months or less. Operating lease ROU assets represents the right to use the leased asset for the lease term and operating lease liabilities are recognized based on the present value of the future minimum lease payments over the lease term at commencement date. As most leases do not provide an implicit rate, the Company use an incremental borrowing rate based on the information available at the adoption date in determining the present value of future payments. Lease expense for minimum lease payments is amortized on a straight-line basis over the lease term and is included in general and administrative expenses in the condensed consolidated statements of operations.
Recent Accounting Pronouncements	Recent Accounting Pronouncements The Company reviewed the recent accounting pronouncements and determined that none of the recent accounting pronouncements were applicable. Management does not believe that any other recently issued, but not yet effective accounting pronouncements, if adopted, would have a material effect on the Company’s consolidated financial statements.

Summary of Significant Accoun_3

Summary of Significant Accounting Policies (Tables)	9 Months Ended
	Jun. 30, 2020
Accounting Policies [Abstract]
Schedule of Anti-dilutive Shares Outstanding	The following potentially dilutive equity securities outstanding as of June 30, 2020 and 2019 were not included in the computation of dilutive loss per common share because the effect would have been anti-dilutive: June 30, 2020 2019 Stock warrants 856,674,588 — Series C-1 preferred stock 445,301,289 — Series C-2 preferred stock 733,542,619 — Series D-1 preferred stock 4,441,433,275 4,392,557,509 Series D-2 preferred stock 41,216,000 — 6,518,167,771 4,392,557,509

Asset Sale and Recapitalizati_2

Asset Sale and Recapitalization Transaction (Tables)	9 Months Ended
	Jun. 30, 2020
Business Combination and Asset Acquisition [Abstract]
Schedule of Assets and Liabilities in Transaction	The cost of the Asset Sale Transaction was allocated to the acquired assets and assumed liabilities based on their estimated fair values. The following assets and liabilities were assumed in the transaction: Cash $ 675,928 Prepaid expense and other current assets 17,539 Total assets acquired 693,467 Accounts payable and other liabilities (40,149 ) Liabilities of discontinued operations (406,662 ) Total liabilities assumed (446,811 ) Net assets acquired $ 246,656

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Schedule of Property and Equipment	Fixed assets consist of the following: Estimated Useful Life in Years June 30, 2020 September 30, 2019 (Unaudited) Laboratory equipment 5 $ 397,432 $ 103,247 Furniture 5 13,367 — Leasehold improvements 5 330,309 216,984 Computer equipment 3 51,503 1,329 792,611 321,560 Less accumulated depreciation (45,556 ) (22,650 ) Property and equipment, net $ 747,055 $ 298,910

Lease Liabilities (Tables)

Lease Liabilities (Tables)	9 Months Ended
	Jun. 30, 2020
Leases [Abstract]
Schedule of Financing Right-of-use Assets	Financing lease right-of-use asset (“Financing ROU”) is summarized below: June 30, 2020 (Unaudited) Financing ROU asset $ 231,841 Less accumulated depreciation (61,936 ) Balance of Financing ROU asset as of June 30, 2020 $ 169,905
Schedule of Financing Lease Liability	Financing lease liability related to the Financing ROU asset is summarized below: June 30, 2020 (Unaudited) Financing lease payables for equipment $ 231,841 Total financing lease payables 231,841 Payments of financing lease liabilities (43,710 ) Total 188,131 Less: short term portion as of June 30, 2020 (40,969 ) Long term portion as of June 30, 2020 $ 147,162
Schedule of Future Minimum Lease Payments of Financing Lease	Future minimum lease payments under the financing lease agreements at June 30, 2020 are as follows: Years ending September 30, Amount 2020 $ 16,452 2021 61,266 2022 61,266 2023 53,787 2024 40,875 2025 4,185 Total minimum financing lease payments 237,831 Less: discount to fair value (49,700 ) Total financing lease payable at June 30, 2020 $ 188,131
Schedule of Operating Right-of-use Assets	Right-of-use asset (“ROU”) is summarized below: June 30, 2020 (Unaudited) Operating office lease $ 231,337 Less accumulated reduction (16,389 ) Balance of ROU asset as of June 30, 2020 $ 214,948
Schedule of Operating Lease Liability	Operating lease liability related to the ROU asset is summarized below: June 30, 2020 (Unaudited) Operating office lease $ 231,337 Total lease liabilities 231,337 Reduction of lease liability (10,414 ) Total 220,923 Less: short term portion as of June 30, 2020 (34,450 ) Long term portion as of June 30, 2020 $ 186,473
Schedule of Future Minimum Lease Payments of Operating Lease	Future base lease payments under the non-cancelable operating lease at June 30, 2020 are as follows: Years ending September 30, Amount 2020 $ 14,634 2021 59,576 2022 61,382 2023 63,236 2024 65,137 2025 27,474 Total minimum non-cancelable operating lease payments 291,439 Less: discount to fair value (70,516 ) Total lease liability at June 30, 2020 $ 220,923

Stockholders' Deficit (Tables)

Stockholders' Deficit (Tables)	9 Months Ended
	Jun. 30, 2020
Equity [Abstract]
Schedule of Warrant Activities	Warrants activities for the nine months ended June 30, 2020 is summarized as follows: Weighted Weighted Average Average Remaining Aggregate Number of Exercise Contractual Intrinsic Warrants Price Term (Years) Value Balance Outstanding at September 30, 2019 — $ — — $ — Warrants issued in connection with the sale of Series D-1 preferred stock 656,674,588 0.002 4.41 — Deemed issuance in connection with the asset sale and recapitalization transaction (see Note 3) 200,000,000 0.003 5.19 — Balance Outstanding at June 30, 2020 856,674,588 $ 0.002 4.59 $ — Exercisable at June 30, 2020 656,674,588 $ 0.002 4.41 $ —

Organization and Nature of Op_2

Organization and Nature of Operations (Details Narrative) - $ / shares

Sep. 22, 2020

Jun. 05, 2020

May 18, 2020

Mar. 31, 2020

Dec. 31, 2019

Jun. 30, 2019

Mar. 31, 2019

Dec. 31, 2018

Jun. 30, 2020

May 28, 2021

Sep. 15, 2020

Sep. 30, 2019

Common stock, shares authorized

12,000,000,000

12,000,000,000

Asset sale transaction percentage

54.55%

Preferred stock, shares authorized

26,667

26,667

Preferred stock, par value

$ 0.0001

$ 0.0001

Common stock, par value

$ 0.0001

$ 0.0001

Subsequent Event [Member]

Common stock, shares authorized

6,666,667

Conversion of common stock shares converted

5,081,549,184

Common stock, par value

$ 0.0001

Subsequent Event [Member] | Minimum [Member]

Common stock, shares authorized

6,666,667

Common stock, par value

$ 0.0001

Subsequent Event [Member] | Maximum [Member]

Common stock, shares authorized

12,000,000,000

Common stock, par value

$ 0.0001

Common Stock [Member]

Number of shares issued during period

Conversion of common stock shares converted

41,216,000

Common Stock [Member] | Subsequent Event [Member] | Minimum [Member]

Common stock, shares authorized

6,666,667

Common stock, par value

$ 0.0001

Common Stock [Member] | Subsequent Event [Member] | Maximum [Member]

Common stock, shares authorized

12,000,000,000

Common stock, par value

$ 0.0001

Series D-1 Preferred Stock [Member]

Preferred stock, par value

$ 0.0001

Preferred stock stated value

9,104.89

Common stock, par value

$ 0.0001

Series D-1 Preferred Stock [Member] | Minimum [Member]

Common stock, shares authorized

6,666,667

Series D-1 Preferred Stock [Member] | Maximum [Member]

Common stock, shares authorized

12,000,000,000

Series D-1 Preferred Stock [Member] | Subsequent Event [Member]

Conversion of common stock shares converted

5,081,549,184

Preferred stock, shares authorized

1,000

Series E Preferred Stock [Member] | Subsequent Event [Member]

Preferred stock, shares authorized

2,000

Preferred stock, par value

$ 0.0001

Preferred stock stated value

$ 2,000

Series D-2 Preferred Stock [Member]

Conversion of common stock shares converted

10,000

Preferred stock, par value

$ 0.0001

Preferred stock stated value

500

Common stock, par value

$ 4,360

Series D-2 Preferred Stock [Member] | Subsequent Event [Member]

Conversion of common stock shares converted

41,216,450

Preferred stock, shares authorized

4,121.6

Asset Purchase Agreement [Member]

Acquisition percentage of issued and outstanding

54.55%

Asset sale transaction percentage

54.55%

Asset Purchase Agreement [Member] | Common Stock [Member]

Conversion of common stock shares converted

5,081,549,184

5,081,549,184

Asset Purchase Agreement [Member] | Series D-1 Preferred Stock [Member]

Number of shares issued during period

1,000

Acquisition percentage of issued and outstanding

54.55%

Common stock, shares authorized

6,666,667

12,000,000,000

Summary of Significant Accoun_4

Summary of Significant Accounting Policies (Details Narrative) - USD ($)	3 Months Ended						9 Months Ended
	Jun. 30, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2020	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Net income (loss)	$ (792,353)	$ (503,430)	$ (541,372)	$ (426,531)	$ (318,448)	$ (468,063)	$ (1,837,155)	$ (1,213,042)
Net cash used in operations							(2,351,823)	(766,021)
Accumulated deficit	(39,848,356)						(39,848,356)		$ (38,011,201)
Stockholders' equity	1,043,510	$ 1,589,207	$ 1,542,637	(1,426,016)	$ (1,279,586)	$ (1,021,138)	1,043,510	(1,426,016)	(632,360)	$ (812,545)
Working capital deficit	218,973						218,973
Cash equivalents
Revenues	24,886						75,896
Allowance for doubtful accounts	$ 0						$ 0		$ 0
Minimum [Member]
Estimated useful lives							3 years
Maximum [Member]
Estimated useful lives							5 years

Summary of Significant Accoun_5

Summary of Significant Accounting Policies - Schedule of Anti-dilutive Shares Outstanding (Details) - shares	9 Months Ended
	Jun. 30, 2020	Jun. 30, 2019
Total antidilutive securities excluded from computation of earnings per share	6,518,167,771	4,392,557,509
Stock Warrants [Member]
Total antidilutive securities excluded from computation of earnings per share	856,674,588
Series C-1 Preferred Stock [Member]
Total antidilutive securities excluded from computation of earnings per share	445,301,289
Series C-2 Preferred Stock [Member]
Total antidilutive securities excluded from computation of earnings per share	733,542,619
Series D-1 Preferred Stock [Member]
Total antidilutive securities excluded from computation of earnings per share	4,441,433,275	4,392,557,509
Series D-2 Preferred Stock [Member]
Total antidilutive securities excluded from computation of earnings per share	41,216,000

Asset Sale and Recapitalizati_3

Asset Sale and Recapitalization Transaction (Details Narrative) - USD ($)	Sep. 22, 2020	Jun. 05, 2020	Mar. 31, 2020	Dec. 31, 2019	Jun. 30, 2019	Mar. 31, 2019	Dec. 31, 2018	Jun. 30, 2020	Sep. 30, 2019
Common stock, shares authorized								12,000,000,000	12,000,000,000
Asset sale transaction percentage		54.55%
Fair value of asset acquired		$ 246,656
Common Stock [Member]
Number of shares issued during period
Conversion of common stock shares converted	41,216,000
Series D-1 Preferred Stock [Member]
Sale of share issued on consideration		1,000
Asset Purchase Agreement [Member]
Acquisition percentage of issued and outstanding		54.55%
Asset sale transaction percentage								54.55%
Asset Purchase Agreement [Member] | Common Stock [Member]
Conversion of common stock shares converted		5,081,549,184						5,081,549,184
Asset Purchase Agreement [Member] | Series D-1 Preferred Stock [Member]
Number of shares issued during period		1,000
Acquisition percentage of issued and outstanding		54.55%
Common stock, shares authorized		6,666,667						12,000,000,000

Asset Sale and Recapitalizati_4

Asset Sale and Recapitalization Transaction - Schedule of Assets and Liabilities in Transaction (Details)	Jun. 30, 2020USD ($)
Business Combination and Asset Acquisition [Abstract]
Cash	$ 675,928
Prepaid expense and other current assets	17,539
Total assets acquired	693,467
Accounts payable and other liabilities	(40,149)
Liabilities of discontinued operations	(406,662)
Total liabilities assumed	(446,811)
Net assets acquired	$ 246,656

Marketable Securities (Details

Marketable Securities (Details Narrative) - USD ($)	3 Months Ended		9 Months Ended		12 Months Ended
	Jun. 30, 2020	Jun. 30, 2019	Jun. 30, 2020	Jun. 30, 2019	Dec. 31, 2017	Sep. 30, 2019
Gain loss on unrealised marketable securities	$ 4,900	$ 9,100	$ 11,200	$ 14,400
Marketable securities	$ 6,800		$ 6,800			$ 18,000
Amarantus BioScience Holdings, Inc. [Member]
Number of shares on acquisition					1,000,000
Fair value of acquisition					$ 40,980

Property and Equipment (Details

Property and Equipment (Details Narrative) - USD ($)	3 Months Ended	9 Months Ended
	Jun. 30, 2020	Jun. 30, 2020
Property, Plant and Equipment [Abstract]
Depreciation and amortization expense	$ 9,675	$ 22,906

Property and Equipment - Schedu

Property and Equipment - Schedule of Property and Equipment (Details) - USD ($)	9 Months Ended
	Jun. 30, 2020	Sep. 30, 2019
Laboratory equipment	$ 397,432	$ 103,247
Furniture	13,367
Leasehold improvements	330,309	216,984
Computer equipment	51,503	1,329
Property and equipment, gross	792,611	321,560
Less accumulated depreciation	(45,556)	(22,650)
Property and equipment, net	$ 747,055	$ 298,910
Laboratory Equipment [Member]
Estimated Useful Life in Years	5 years
Furniture [Member]
Estimated Useful Life in Years	5 years
Leasehold Improvements [Member]
Estimated Useful Life in Years	5 years
Computer Equipment [Member]
Estimated Useful Life in Years	3 years

Loans Payable (Details Narrativ

Loans Payable (Details Narrative) - Loan Agreement [Member] - USD ($)	1 Months Ended
	Sep. 30, 2017	Jun. 30, 2020
Proceeds from borrowed loans	$ 1,000
Debt instrument, interest rate	33.30%
Loan principal		$ 1,000
Interest payable		$ 938

Lease Liabilities (Details Narr

Lease Liabilities (Details Narrative) - USD ($)	1 Months Ended					3 Months Ended	9 Months Ended
	Jan. 31, 2020	Dec. 31, 2019	Aug. 31, 2019	Mar. 31, 2019	Nov. 30, 2018	Jun. 30, 2020	Jun. 30, 2020	Sep. 30, 2019
Lease description							The lease is for a period of 60 months commencing in February 2020 and expiring in February 2025.
Depreciation expense financing ROU asset						$ 11,788	$ 34,154
Right-of-use assets						214,948	214,948
Lease liabilities						$ 220,923	220,923
Lease cost							19,513
Base lease cost							10,414
Lease other expense							$ 9,099
Operating discount rates						12.00%	12.00%
Accounting Standards Update 2016-02 [Member]
Right-of-use assets						$ 231,337	$ 231,337
Lease liabilities						$ 231,337	$ 231,337
Minimum [Member]
Finance discount rates						8.00%	8.00%
Maximum [Member]
Finance discount rates						15.00%	15.00%
Financing Agreement [Member] | First Lessor [Member]
Monthly base rent					$ 379
Lease term					60 months
Lease expiration					Oct. 31, 2023
Lease description					60 months commencing in November 2018 through October 2023.
Financing lease payable					$ 16,064
Financing Agreement [Member] | Second Lessor [Member]
Monthly base rent					$ 1,439
Lease term					60 months
Lease expiration					Oct. 31, 2023
Lease description					60 months commencing in November 2018 through October 2023.
Financing lease payable					$ 62,394
Financing Agreement [Member] | Third Lessor [Member]
Monthly base rent				$ 1,496
Lease term				60 months
Lease expiration				Oct. 31, 2023
Lease description				60 months commencing in March 2019 through April 2024.
Financing lease payable				$ 64,940
Financing Agreement [Member] | Fourth Lessor [Member]
Monthly base rent			$ 397
Lease term			60 months
Lease expiration			Oct. 31, 2023
Lease description			60 months commencing in August 2019 through August 2024.
Financing lease payable			$ 19,622
Financing Agreement [Member] | Fifth Lessor [Member]
Monthly base rent	$ 1,395
Lease term	60 months
Lease expiration	Oct. 31, 2023
Lease description	60 months commencing in January 2020 through December 2024.
Financing lease payable	$ 68,821
Lease Agreement [Member]
Lease term						60 months	60 months
Lease expiration		Feb. 28, 2025					Feb. 28, 2025
Lease description							The lease is for a period of 60 months commencing in February 2020 and expiring in February 2025.
Lease Agreement [Member] | First Year [Member]
Monthly base rent		$ 4,878
Lease Agreement [Member] | Second Year [Member]
Monthly base rent		5,026
Lease Agreement [Member] | Third Year [Member]
Monthly base rent		5,179
Lease Agreement [Member] | Fourth Year [Member]
Monthly base rent		5,335
Lease Agreement [Member] | Fifth Year [Member]
Monthly base rent		$ 5,495

Lease Liabilities - Schedule of

Lease Liabilities - Schedule of Financing Right-of-use Assets (Details) - USD ($)	Jun. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Financing ROU asset	$ 231,841
Less accumulated depreciation	(61,936)
Balance of Financing ROU asset as of June 30, 2020	$ 169,905	$ 204,059

Lease Liabilities - Schedule _2

Lease Liabilities - Schedule of Financing Lease Liability (Details) - USD ($)	Jun. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Financing lease payables for equipment	$ 231,841
Total financing lease payables	231,841
Payments of financing lease liabilities	(43,710)
Total	188,131
Less: short term portion as of June 30, 2020	(40,969)	$ (35,096)
Long term portion as of June 30, 2020	$ 147,162	$ 178,350

Lease Liabilities - Schedule _3

Lease Liabilities - Schedule of Future Minimum Lease Payments of Financing Lease (Details)	Jun. 30, 2020USD ($)
Leases [Abstract]
2020	$ 16,452
2021	61,266
2022	61,266
2023	53,787
2024	40,875
2025	4,185
Total minimum financing lease payments	237,831
Less: discount to fair value	(49,700)
Total financing lease payable at June 30, 2020	$ 188,131

Lease Liabilities - Schedule _4

Lease Liabilities - Schedule of Operating Right-of-use Assets (Details) - USD ($)	Jun. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Operating office lease	$ 231,337
Less accumulated reduction	(16,389)
Balance of ROU asset as of June 30, 2020	$ 214,948

Lease Liabilities - Schedule _5

Lease Liabilities - Schedule of Operating Lease Liability (Details) - USD ($)	Jun. 30, 2020	Sep. 30, 2019
Leases [Abstract]
Operating office lease	$ 231,337
Total lease liabilities	231,337
Reduction of lease liability	(10,414)
Total	220,923
Less: short term portion as of June 30, 2020	(34,450)
Long term portion as of June 30, 2020	$ 186,473

Lease Liabilities - Schedule _6

Lease Liabilities - Schedule of Future Minimum Lease Payments of Operating Lease (Details)	Jun. 30, 2020USD ($)
Leases [Abstract]
2020	$ 14,634
2021	59,576
2022	61,382
2023	63,236
2024	65,137
2025	27,474
Total minimum non-cancelable operating lease payments	291,439
Less: discount to fair value	(70,516)
Total lease liability at June 30, 2020	$ 220,923

Related-Party Transactions (Det

Related-Party Transactions (Details Narrative)	Jun. 05, 2020USD ($)
Consulting Agreement [Member] | Mr. Kucharchuk [Member]
Compensation to related party	$ 15,000

Stockholders' Deficit (Details

Stockholders' Deficit (Details Narrative)	Jun. 05, 2021shares	Sep. 22, 2020$ / sharesshares	May 18, 2020$ / sharesshares	Aug. 20, 2015shares	Jun. 30, 2020USD ($)$ / sharesshares	Jun. 30, 2019USD ($)	May 28, 2021shares	Sep. 24, 2020shares	Jun. 05, 2020$ / sharesshares	Sep. 30, 2019$ / sharesshares	Mar. 07, 2017$ / sharesshares	Feb. 18, 2011shares
Common stock, shares authorized					12,000,000,000					12,000,000,000
Common stock, par value | $ / shares					$ 0.0001					$ 0.0001
Preferred stock, shares authorized					26,667					26,667
Preferred stock, shares issued					13,672					992
Preferred stock, shares outstanding					13,672					992
Preferred stock, par value | $ / shares					$ 0.0001					$ 0.0001
Proceeds from sale of stock | $					$ 2,590,000	$ 599,470
Common stock, shares issued					1,398,070					0
Common stock, shares outstanding					1,398,070					0
Stock Option [Member]
Number of option granted
Fair market value of share on grant date percentage					110.00%
2011 Stock Option Plan [Member]
Number of option authorized to purchase common stock												57
Common Stock [Member]
Conversion of common stock shares converted		41,216,000
Number of shares issuable	1,398,070
Common stock, shares issued					1,398,070
Common stock, shares outstanding					1,398,070
Stock Warrants [Member]
Warrants issued					856,674,588				656,674,588
Warrants exercise price per share | $ / shares									$ 0.00214
Warrant maturity date									Nov. 27, 2024
Warrants outstanding					856,674,588
Two Investors [Member] | Stock Warrants [Member]
Warrants issued									200,000,000
Warrants exercise price per share | $ / shares									$ 0.00214
Warrant term									5 years
Series A Preferred Stock [Member]
Preferred stock designated				1,333
Preferred stock, shares authorized				26,667
Stockholder voting rights				Each holder of Series A Preferred Stock is entitled to 500 votes for each share of Series A Preferred Stock held as of the applicable date on any matter that is submitted to a vote or for the consent of the stockholders of the Company. The holders of Series A Preferred Stock shall have no special voting rights and their consent is not required (except to the extent they are entitled to vote with holders of Common Stock as set forth herein) for the taking of any corporate action.
Preferred stock, shares issued									667
Series A Preferred Stock [Member] | Board of Directors [Member]
Preferred stock, shares issued					667
Preferred stock, shares outstanding					667
Series B Preferred Stock [Member]
Preferred stock designated											10,523
Preferred stock, par value | $ / shares											$ 0.0001
Preferred stock stated value | $ / shares											$ 0.0001
Series C-1 Preferred Stock [Member]
Preferred stock designated			3,000
Preferred stock, shares issued					2,966.2212				2,966.2212
Preferred stock, shares outstanding					2,966.2212
Preferred stock, par value | $ / shares			$ 0.0001
Preferred stock stated value | $ / shares			$ 4,128.42
Preferred stock description			Each share of Series C-1 Preferred Stock is convertible into shares of common stock any time after the Initial Issuance Date at a conversion price of $0.0275 per share. The number of shares of common stock issuable upon conversion shall be determined by dividing (x) the conversion amount (determined by the sum of the stated value thereof plus any additional amount thereon which consist of all dividends, whether declared or not) of such share of Series C-1 by (y) the conversion price of $0.0275 per share (subject to temporary adjustment upon a triggering event as defined by the Series C-1 Certificate of Designation, to 80% of the conversion price). The adjusted conversion price is only in effect until the triggering event is cured. The convertibility of shares of Series C-1 Preferred Stock is limited such that a holder of Series C-1 Preferred Stock may not convert Series C-1 Preferred Stock to common stock to the extent that the number of shares of common stock to be issued pursuant to such conversion, when aggregated with all other shares of common stock owned by the holder at such time, would result in the holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934) more than 4.99% of all of the Company's common stock outstanding.
Conversion price | $ / shares			$ 0.0275
Conversion percentage			0.80
Series C-2 Preferred Stock [Member]
Preferred stock designated			6,000
Preferred stock, shares issued					4,916.865				4,916.865
Preferred stock, shares outstanding					4,916.865
Preferred stock, par value | $ / shares			$ 0.0001
Preferred stock stated value | $ / shares			$ 410.27
Preferred stock description			Each share of Series C-2 Preferred Stock is convertible into shares of common stock any time after the initial issuance date at a conversion price of $0.00275 per share. The number of shares of common stock issuable upon conversion shall be determined by dividing (x) the conversion amount (determined by the sum of the stated value thereof plus any additional amount thereon) of such share of Series C-2 by (y) the conversion price of $0.00275 per share (subject to temporary adjustment upon a triggering event as defined by the Series C-2 Certificate of Designation to 80% of the conversion price). The adjusted conversion price is only in effect until the triggering event is cured. The convertibility of shares of Series C-2 Preferred Stock is limited such that a holder of Series C-2 Preferred Stock may not convert Series C-2 Preferred Stock to common stock to the extent that the number of shares of common stock to be issued pursuant to such conversion, when aggregated with all other shares of common stock owned by the holder at such time, would result in the holder beneficially owning (as determined in accordance with Section 13(d) of the Securities Exchange Act of 1934) more than 4.99% of all of the Company's common stock outstanding.
Conversion price | $ / shares			$ 0.00275
Series D-1 Preferred Stock [Member]
Common stock, par value | $ / shares			$ 0.0001
Preferred stock designated			1,000
Preferred stock, shares issued					1,000
Preferred stock, shares outstanding					1,000
Preferred stock, par value | $ / shares			$ 0.0001
Preferred stock stated value | $ / shares			$ 9,104.89
Pro-rata description			Each share of Series D-1 Preferred Stock is convertible into a pro rata portion of 54.55% of the Fully Diluted Equity (as defined in the Series D-1 Certificate of Designation) of the Company upon the effectiveness of the amendment to the Company's Articles of Incorporation to increase the Company's authorized common stock, par value $0.0001 per share, from 6,666,667 shares to 12,000,000,000 shares, which occurred on September 24, 2020 ( the "Conversion Date").
Conversion of debt amount | $					$ 676,369
Proceeds from sale of stock | $					$ 2,590,000
Series D-2 Preferred Stock [Member]
Common stock, par value | $ / shares			$ 4,360
Preferred stock, shares issued					4,121.64				4,121.64
Preferred stock, shares outstanding					4,121.64
Preferred stock, par value | $ / shares			0.0001
Preferred stock stated value | $ / shares			$ 500
Conversion of common stock shares converted			10,000
Minimum [Member] | Series C-1 Preferred Stock [Member]
Conversion price | $ / shares			$ 0.00275
Minimum [Member] | Series D-1 Preferred Stock [Member]
Common stock, shares authorized			6,666,667
Maximum [Member] | Board of Directors [Member] | 2011 Stock Option Plan [Member]
Number of option authorized to purchase common stock												14
Maximum [Member] | Series C-1 Preferred Stock [Member]
Common stock outstanding, percentage			4.99%
Maximum [Member] | Series C-2 Preferred Stock [Member]
Common stock outstanding, percentage			4.99%
Maximum [Member] | Series D-1 Preferred Stock [Member]
Common stock, shares authorized			12,000,000,000
Subsequent Event [Member]
Common stock, shares authorized		6,666,667
Common stock, par value | $ / shares		$ 0.0001
Conversion of common stock shares converted		5,081,549,184
Subsequent Event [Member] | Stock Option [Member]
Common stock were be reserved for issuance under the plan								3,043,638,781
Number of stock options issued and outstanding
Subsequent Event [Member] | Series D-1 Preferred Stock [Member]
Preferred stock, shares authorized		1,000
Conversion of common stock shares converted							5,081,549,184
Subsequent Event [Member] | Series D-2 Preferred Stock [Member]
Preferred stock, shares authorized		4,121.6
Conversion of common stock shares converted							41,216,450
Subsequent Event [Member] | Minimum [Member]
Common stock, shares authorized		6,666,667
Common stock, par value | $ / shares		$ 0.0001
Subsequent Event [Member] | Minimum [Member] | Common Stock [Member]
Common stock, shares authorized		6,666,667
Common stock, par value | $ / shares		$ 0.0001
Subsequent Event [Member] | Maximum [Member]
Common stock, shares authorized		12,000,000,000
Common stock, par value | $ / shares		$ 0.0001
Subsequent Event [Member] | Maximum [Member] | Common Stock [Member]
Common stock, shares authorized		12,000,000,000
Common stock, par value | $ / shares		$ 0.0001

Stockholders' Deficit - Schedul

Stockholders' Deficit - Schedule of Warrant Activities (Details) - Stock Warrants [Member]	9 Months Ended
	Jun. 30, 2020USD ($)$ / sharesshares
Number of Warrants, Outstanding Beginning balance | shares
Number of Warrants, Warrants issued in connection with the sale of Series D-1 preferred stock | shares	656,674,588
Number of Warrants, Deemed issuance in connection with the asset sale and recapitalization transaction (see Note 3) | shares	200,000,000
Number of Warrants, Outstanding Ending balance | shares	856,674,588
Number of Warrants, Exercisable | shares	656,674,588
Weighted Average Exercise Price, Outstanding Beginning balance | $ / shares
Weighted Average Exercise Price, Warrants issued in connection with the sale of Series D-1 preferred stock | $ / shares	0.002
Weighted Average Exercise Price, Deemed issuance in connection with the asset sale and recapitalization transaction (see Note 3) | $ / shares	0.003
Weighted Average Exercise Price, Outstanding Ending balance | $ / shares	0.002
Weighted Average Exercise Price, Exercisable | $ / shares	$ 0.002
Weighted Average Remaining Contractual Term (Years), Beginning Balance Outstanding	0 years
Weighted Average Remaining Contractual Term (Years), Warrants issued in connection with the sale of Series D-1 preferred stock	4 years 4 months 28 days
Weighted Average Remaining Contractual Term (Years), Deemed issuance in connection with the asset sale and recapitalization transaction (see Note 3)	5 years 2 months 8 days
Weighted Average Remaining Contractual Term (Years), Ending Balance Outstanding	4 years 7 months 2 days
Weighted Average Remaining Contractual Term (Years), Exercisable	4 years 4 months 28 days
Aggregate Intrinsic Value, Beginning Balance Outstanding | $
Aggregate Intrinsic Value, Ending Balance Outstanding | $
Aggregate Intrinsic Value, Exercisable | $

Commitment and Contingencies (D

Commitment and Contingencies (Details Narrative) - USD ($)	Jun. 05, 2020	Dec. 31, 2019	Jun. 30, 2020
Lease description			The lease is for a period of 60 months commencing in February 2020 and expiring in February 2025.
Contingent liability	$ 62,240
Employment Agreement [Member] | Restricted Stock Units (RSUs) [Member]
Number of stock option shares granted
Employment Agreement [Member] | Stock Option [Member]
Number of stock option shares granted
Busch Employment Agreement [Member] | Restricted Stock Units (RSUs) [Member]
Number of stock option shares granted
Busch Employment Agreement [Member] | Stock Option [Member]
Number of stock option shares granted
Lease Agreement [Member]
Lease description			The lease is for a period of 60 months commencing in February 2020 and expiring in February 2025.
Lease term			60 months
Lease expiration		Feb. 28, 2025	Feb. 28, 2025
Dr. Michael Ruxin [Member] | Employment Agreement [Member]
Salaries	$ 300,000
Annual decretionary bonus percentage	150.00%
Dr. Michael Ruxin [Member] | Employment Agreement [Member] | Restricted Stock Units (RSUs) [Member] | 2020 Equity Incentive Plan [Member]
Number of stock option shares granted	49,047,059
Dr. Michael Ruxin [Member] | Employment Agreement [Member] | Stock Option [Member] | 2020 Equity Incentive Plan [Member]
Number of stock option shares granted	420,691,653
Jeffrey Busch [Member] | Busch Employment Agreement [Member]
Salaries	$ 60,000
Jeffrey Busch [Member] | Busch Employment Agreement [Member] | Restricted Stock Units (RSUs) [Member] | 2020 Equity Incentive Plan [Member]
Number of stock option shares granted	49,047,059
Jeffrey Busch [Member] | Busch Employment Agreement [Member] | Stock Option [Member] | 2020 Equity Incentive Plan [Member]
Number of stock option shares granted	420,691,653

Subsequent Events (Details Narr

Subsequent Events (Details Narrative)

Dec. 31, 2021USD ($)

Sep. 30, 2021USD ($)shares

May 12, 2021USD ($)$ / sharesshares

Jan. 15, 2021USD ($)shares

Dec. 12, 2020USD ($)

Sep. 24, 2020USD ($)shares

Sep. 16, 2020USD ($)Integer$ / sharesshares

Sep. 15, 2020Integer$ / sharesshares

Jun. 05, 2020$ / sharesshares

Apr. 14, 2021USD ($)$ / sharesshares

Mar. 31, 2020USD ($)shares

Dec. 31, 2019USD ($)shares

Jun. 30, 2019USD ($)shares

Mar. 31, 2019USD ($)shares

Dec. 31, 2018USD ($)shares

Jun. 09, 2021$ / shares

Sep. 22, 2020$ / sharesshares

Jun. 30, 2020$ / sharesshares

May 18, 2020$ / sharesshares

Sep. 30, 2019$ / sharesshares

Subsequent Event [Line Items]

Preferred stock, par value | $ / shares

$ 0.0001

$ 0.0001

Preferred stock, shares authorized

26,667

26,667

Aggregate investment amount | $

$ 390,000

$ 2,200,000

$ 280,000

$ 60,000

$ 259,470

Common stock, shares authorized

12,000,000,000

12,000,000,000

Common stock, par value | $ / shares

$ 0.0001

$ 0.0001

Mr. Chilcott [Member] | Forecast [Member]

Subsequent Event [Line Items]

Eligibility of bonuses | $

$ 15,000

$ 20,000

Raise of capital

10,000,000

Eligibility bonus description

$15,000 if the Company successfully lists on a Nasdaq stock market on or before December 31, 2021

$20,000 if the Company completes a capital raise of at least $10,000,000 on or prior to September 30, 2021

Common Stock [Member]

Subsequent Event [Line Items]

Number of shares issued during period

Aggregate investment amount | $

Stock Warrants [Member]

Subsequent Event [Line Items]

Warrants outstanding

856,674,588

Warrant exercise price | $ / shares

$ 0.00214

Series D-1 Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock, par value | $ / shares

$ 0.0001

Common stock, par value | $ / shares

$ 0.0001

Sale of stock issued

1,000

Series D-1 Preferred Stock [Member] | Maximum [Member]

Subsequent Event [Line Items]

Common stock, shares authorized

12,000,000,000

Series D-2 Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock, par value | $ / shares

$ 0.0001

Common stock, par value | $ / shares

$ 4,360

Subsequent Event [Member]

Subsequent Event [Line Items]

Common stock, shares authorized

6,666,667

Common stock, par value | $ / shares

$ 0.0001

Subsequent Event [Member] | Series C-2 Preferred Stock [Member]

Subsequent Event [Line Items]

Conversion price | $ / shares

$ 0.00275

Subsequent Event [Member] | Maximum [Member]

Subsequent Event [Line Items]

Common stock, shares authorized

12,000,000,000

Common stock, par value | $ / shares

$ 0.0001

Subsequent Event [Member] | Mr. Chilcott [Member]

Subsequent Event [Line Items]

Salaries | $

$ 225,000

Eligibility of bonuses | $

$ 5,000

$ 5,000

$ 5,000

Raise of capital

3,000,000

Eligibility bonus description

$5,000 if the Company completes a capital raise of at least $3,000,000 on or prior to Apri1 15, 2021

5,000 if the Company files a registration statement on Form S-1 on or prior to January 15, 2021;

$5,000 if the Company's next Annual Report on Form 10-K is filed on or prior to December 12, 2020;

Subsequent Event [Member] | Mr. Chilcott [Member] | Maximum [Member]

Subsequent Event [Line Items]

Number of stock option shares granted

94,545,096

Subsequent Event [Member] | Common Stock [Member] | Maximum [Member]

Subsequent Event [Line Items]

Common stock, shares authorized

12,000,000,000

Common stock, par value | $ / shares

$ 0.0001

Subsequent Event [Member] | Securities Purchase Agreement [Member] | Convertible Note [Member]

Subsequent Event [Line Items]

Debt instrument, face amount | $

$ 1,000,000

Default interest rate

10.00%

Debt instrument, interest rate

8.00%

Debt instrument, maturity date

May 12, 2026

Prepaymet percentage of outstanding principal and accrued interest

110.00%

Debt instrument, convertible conversion price | $ / shares

$ 0.00313

Subsequent Event [Member] | Securities Purchase Agreement [Member] | Stock Warrants [Member]

Subsequent Event [Line Items]

Aggregate investment amount | $

$ 1,000,000

Warrant exercise price | $ / shares

$ 0.00313

Subsequent Event [Member] | Securities Purchase Agreement [Member] | Stock Warrants [Member] | Maximum [Member]

Subsequent Event [Line Items]

Warrants outstanding

63,897,764

Subsequent Event [Member] | Subscription Agreement [Member] | Common Stock [Member] | Fourteen Accredited Investors [Member]

Subsequent Event [Line Items]

Common stock, par value | $ / shares

$ 0.0001

Sale of stock issued

431,309,904

Sale of stock price per share | $ / shares

$ 0.00313

Aggregate purchase price | $

$ 1,350,000

Subsequent Event [Member] | Series E Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock, par value | $ / shares

$ 0.0001

Preferred stock, shares authorized

2,000

Stated value of preferred stock | $ / shares

$ 2,000

Dividend rate

8.00%

Dividend description

From the initial issuance date, cumulative dividends on each share of Series E shall accrue, on a quarterly basis in arrears (with any partial quarter calculated on a pro-rata basis), at the rate of 8% per annum on the Stated Value, plus any additional amount thereon. Dividends shall be paid within 15 days after the end of each fiscal quarter ("Dividend Payment Date"), at the option of the Holder in cash or through the issuance of shares of common stock.

Number of trading days | Integer

5

Conversion of preferred stock

Each share of Series E Preferred Stock is convertible into shares of common stock any time after the initial issuance date at athe Conversion Price which is the lesser of: (i) $0.00375 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principal market, subject to adjustment as provided in the Series E Certificate of Designation. Provided, however, the Conversion Price shall never be less than $0.0021. The number of shares of common stock issuable upon conversion shall be determined by dividing (x)multiplying the conversion amount (determinednumber of outstanding shares by the sum of the stated value thereof plus any additional amount thereon) of suchper share of Series E$2,000 plus accrued dividends and dividing that number by (y) the Conversion Price.

Subsequent Event [Member] | Series E Preferred Stock [Member] | Securities Purchase Agreement [Member]

Subsequent Event [Line Items]

Stated value of preferred stock | $ / shares

$ 2,000

Dividend rate

8.00%

Number of trading days | Integer

5

Conversion of preferred stock

The number of shares of common stock issuable up on conversion of the Series E Preferred is determined by dividing the stated value of the number of shares being converted, plus any accrued and unpaid dividends, by the lesser of: (i) $0.00375 and (ii) 75% of the average closing price of the Company's common stock during the prior five trading days; provided, however, the conversion price shall never be less than $0.0021.

Number of shares issued during period

1,000

Aggregate investment amount | $

$ 2,000,000

Common stock, shares authorized

12,000,000,000

Subsequent Event [Member] | Series E Preferred Stock [Member] | Qualified Public Offering [Member]

Subsequent Event [Line Items]

Conversion of preferred stock

(i) a Change of Control of the Corporation or (ii) on the closing of, a Qualified Public Offering by the Corporation, all of the outstanding shares of Series E (including any fraction of a share) shall automatically convert into an aggregate number of shares of Common Stock (including any fraction of a share) by multiplying the number of outstanding shares by $2,000 plus accrued interest and expenses and dividing that number (including any fraction of a share) by the lesser of: (i) $0.00375 or (ii) 75% of the average closing price of the common stock during the prior five trading days on the principle market. However, the conversion price shall never be less than $0.0021.

Subsequent Event [Member] | Series D-1 Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock, shares authorized

1,000

Subsequent Event [Member] | Series D-1 Preferred Stock [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Common stock issued upon the conversion, shares

5,081,549,184

Subsequent Event [Member] | Series D-2 Preferred Stock [Member]

Subsequent Event [Line Items]

Preferred stock, shares authorized

4,121.6

Subsequent Event [Member] | Series D-2 Preferred Stock [Member] | Common Stock [Member]

Subsequent Event [Line Items]

Common stock issued upon the conversion, shares

41,216,000